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This project is mainly about the impact of genomic variation on one typical side effect and to 
some extent on the efficacy of an important new class of drugs inhibiting the epidermal growth 
factor receptor (EGFR). This receptor is a member of receptor tyrosine kinases (RTK) family 
(Hynes and Lane 2005). It contains an extracellular site including a domain for binding to its 
ligands, a single membrane region and a cytoplasmic region. The cytoplasmic region contains a 
tyrosine kinase domain. Binding of the specific ligands will activate the kinase activity of the 
intracellular region. Its activation initiates EGFR’s signaling pathway (Olayioye et al. 2000, 
Schlessinger 2004, Yarden and Sliwkowski 2001).  
The EGFR is important in numerous types of cancer such as breast cancer, head-and-neck cancer, 
non-small cell lung cancer (NSCLC), renal cancer, ovarian cancer, esophageal cancer and colon 
cancer (Herbst and Langer 2002, Sizeland and Burgess 1992). These types of cancer for example 
are still difficult to cure; however, efficacy of therapy and – remarkably – its tolerance are 
moderately improved using the new class of drugs which target EGFR. As a result of this approach, 
some of the classical side effects of chemotherapy (e.g. hair loss or mucositis) are not observed 
or observed with lower incidence and severity. On the other hand, there are certain adverse 
effects related to this class of targeted therapy including skin toxicity. However, the frequency of 
adverse drug reactions as well as the efficacy of treatment is not the same in all subjects receiving 
these drugs.  
Genomic variation may explain why some people respond better and other respond worse to this 
therapy. Interestingly, there is an obvious positive correlation between existence and severity of 
skin toxicity and survival of the patients. This may underline the role of germline genetic 
variations considering the individually variable extent of skin toxicity. In the following text the 
EGFR and its ligands, possible mechanisms in which the skin toxicity might be formed, the impact 
of genetic variation in developing traits and diseases, and a summary of methods used for 




1.1 Epidermal growth factor receptor inhibitors as anti-cancer drugs 
1.1.1 Epidermal growth factor receptor structure 
The presence of epidermal growth factor (EGF) binding site on the cell surface was confirmed in 
1975 using radio-labeled EGF in fibroblasts (Carpenter et al. 1975). Later on, the function of the 
EGF receptor (EGFR) was thoroughly investigated and in vivo effects of EGFR targeting was 
surveyed in mouse models. Knocking out EGFR in different setting resulted in severe 
abnormalities such as embryonic lethality (Threadgill et al. 1995), or epithelial growth and 
development failure of the skin, the lung and the gastrointestinal (GI) tract (Miettinen et al. 1995, 
Sibilia and Wagner 1995, Threadgill et al. 1995). The numerous severe abnormalities associated 
with absence of EGFR testify for the wide range of roles of EGFR in development of epithelial 
cells.    
 
The EGFR also known as ERBB-1 (Erythroblastic Leukemia Viral Oncogene Homolog) is a member 
of ERBB subclass of receptor tyrosine kinases (Hynes and Lane 2005). It has a single membrane 
region and an extracellular site for binding to its ligands. The cytoplasmic region contains a 
tyrosine kinase domain. Binding of the specific ligands will activate the kinase activity of the 
intracellular region. Upon activation, the kinase domain will phosphorylate tyrosine residues on 
the same molecule (autophosphorylation). Subsequently, homo- (with another EGFR) or hetero- 
(with another member of ERBB family) dimerization will take place. This dimerization facilitates 
the beginning of a kinase cascade responsible for activation of EGFR’s downstream signaling 
pathway (Olayioye et al. 2000, Schlessinger 2004, Yarden and Sliwkowski 2001).  
 
1.1.2 EGFR in human cancer  
Overexpression and deregulation of EGFR were noticed in several epithelial tumors such as breast 
cancer, NSCLC, renal cancer, ovarian cancer, esophageal cancer and colon cancer (Herbst and 
Langer 2002, Sizeland and Burgess 1992). Furthermore, several single nucleotide variations 
(SNVs) were found in the EGFR which could increase the kinase activity of this receptor in human 
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cancers (Gill et al. 1984, Humphrey et al. 1990). Therefore, the EGFR was targeted as an 
anticancer strategy (Masui et al. 1984b).  
Two classes of EGFR inhibitors are now applied in clinical practice: Monoclonal antibodies, and 
Small molecule inhibitors. 
1.1.2.1 Monoclonal antibody EGFR inhibitors 
These antibodies bind to the extracellular region of the receptor which has the role of ligand 
binding. This competition between the drug and EGFR ligands will turn off the downstream 
signaling pathway (Li et al. 2005, Normanno et al. 2003). Cetuximab and panitumumab are two 
approved drugs from this class. Cetuximab is a human-mouse chimeric monoclonal antibody 
(IgG1 subtype) which was approved by the FDA for treatment of advanced colorectal cancer and 
locally advanced squamous cell carcinoma (SCC) of head and neck (HNSCC) (Blick and Scott 2007, 
Wong 2005). Panitumumab was approved by the FDA in 2006 for treatment of patients with 
metastatic colorectal cancer having disease progression after chemotherapy; although, later on 
treatment was limited to KRAS wild-type cancers (Hocking and Price 2014). 
 
1.1.2.2 Small-molecule EGFR inhibitors 
Small-molecule inhibitors or tyrosine kinase inhibitors (TKIs) inhibit the activity of the intra-
cellular tyrosine-kinase domain of the receptor by attaching to its ATP binding site. Erlotinib and 
gefitinib are two examples of this drug category. Erlotinib was approved by FDA in 2004 for 
treatment of patients with locally advanced or metastatic non-small cell lung carcinoma (NSCLC) 
(Cataldo et al. 2011). Recently it has also been approved as first-line treatment of pancreatic 
cancer in combination with gemcitabine (Ciardiello and Tortora 2008). Gefitinib was approved by 
the FDA already in 2003; however, because of failure in clinical trials its usage is limited to 




1.2 Adverse effects of EGFR inhibition therapy; Skin rash 
In general, adverse effects of EGFR targeted therapy are often less severe and this therapy is 
better tolerated than cytostatic (cytotoxic) chemotherapy. Classical adverse effects of cytostatic 
chemotherapy, such as bone marrow suppression, alopecia and mucositis are not observed 
during EGFR inhibitor monotherapy. Since EGFR is mostly expressed in epidermal or endothelial 
cells and has important physiological roles, its inhibition results in adverse effects such as skin 
toxicity, and diarrhea. Additionally hypomagnesemia is found as another side effect (Cunningham 
et al. 2004, Goldberg et al. 2004, Parmar et al. 2013, Schrag et al. 2005, Van Cutsem et al. 2007). 
A summary of adverse effect prevalence is displayed in Table 1.2.1.  
Table 1.2.1 Adverse effects of EGFR inhibition therapy. Hypomagnesemia is not reported in small molecule tyrosine kinase 
inhibitors.  
 Erlotinib Gefitinib Cetuximab Panitumumab Control 
group 
Skin rash 50% 
[monotherapy] 








et al. 2013)  
31% 
[monotherapy] 


















 FOLFIRI, and 
irinotecan] (Boku 
et al. 2014)  
53% 
[monotherapy] 







et al. 2013) 
Diarrhea  18% (Ciuleanu et 
al. 2012) 
23% (Nakagawa et 
al. 2012) 
29% (Shi et al. 
2013)  
22% (Mohamed et 
al. 2005b) 
15.1% (Ishiguro et 
al. 2012)  
28% (Kim et al. 
2013)  
9% (Van Cutsem et 
al. 2008)  




– – 11% (Ishiguro et 
al. 2012)  
21% (Kim et al. 
2013) 
36% (Boku et al. 
2014) 
29% (Van Cutsem 
et al. 2008) 




Diarrhea occurs in up to 29% of patients treated with EGFR inhibitors (Table 1.2.1). In case of 
diarrhea, loperamide was frequently used as a treatment; however, diarrhea remains to be one 
of the dose-limiting events (Ciardiello et al. 1999, ImClone Systems Incorporated 2006, Kim, E et 
al. 2008, Shepherd et al. 2005). Diarrhea is a frequent adverse effect of some cytostatic 
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chemotherapeutic agents such as 5-fluorouracil or irinotecan; thus, not all studies applying EGFR 
inhibitor combination therapies are informative. However, as an example of EGFRI monotherapy, 
in TITAN study (a randomized multicenter phase 3 of non-small-cell lung cancer with poor 
prognosis) diarrhea has occurred in 18% of patients with erlotinib monotherapy compared to 2% 
of patients with docetaxel or permetrexed chemotherapy regimens (Ciuleanu et al. 2012). . On 
the other hand, in (Ishiguro et al. 2012) study only 5% of patients treated with cetuximab 
monotherapy had diarrheas compared to 18% in case of combination of cetuximab with 
irinotecan or FOLFIRI (folinic acid, fluorouracil and irinotecan chemotherapy regimen). This 
finding shows that when considering diarrhea, side effects of cytotoxic agents should also be 
regarded. The underlying mechanisms are not well understood. One suggested mechanism is 
that EGFR inhibition leads to excessive chloride secretion in the intestine and therefore causes a 
secretory diarrhea (Uribe et al. 1996).  
 
1.2.2 Hypomagnesemia 
Hypomagnesemia was not primarily reported as a side effect of EGFR inhibition and was 
surprisingly only recognized as a frequent problem after approval of these drugs. Retrospective 
surveys have shown hypomagnesemia in 50–65% of patients receiving anti EGFR monoclonal 
antibodies (Jean and Shah 2008). This side effect only occurs in case of using monoclonal 
antibodies against EGFR but not other targeted therapies using monoclonal antibodies. 
Contrasting to the anti-EGFR antibodies, there is no evidence of an association between the 
tyrosine kinase inhibitors gefitinib, erlotinib and hypomagnesaemia (Costa et al. 2011). 
Hypomagnesemia occurs at 6–8 weeks after commencement of EGFR monoclonal antibody 
therapy (Fakih et al. 2006). This side effect is caused by decreased reabsorption of magnesium in 
distal tubules of kidney nephrons and therefore renal wasting of magnesium. EGFR activation is 
necessary for function of TRPM6 (an epithelial Mg2+ channel) and therefore its inhibition causes 
hypomagnesemia (Costa et al. 2011). 
Other less common side effect are fatigue, asthenia, dyspnea, abdominal pain, nausea, and 
anorexia (Fakih et al. 2006). 
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1.2.3 Skin rash as the main side effect 
Skin rash is clinically the most noteworthy side effect of EGFR therapy. Other skin related 
toxicities are xerosis, paronychia, hair changes, and telangiectasias (Tsimboukis et al. 2009). 
Occurrence of rash negatively affects the patients’ compliance to the treatment. Particularly if 
occurring more extensively, skin rash significantly compromises the patient’s quality of life and 
thereby may have a negative impact on treatment’s outcome (Nanney et al. 1990a, Nanney et al. 
1990b). Minor forms of EGFR inhibition associated rash occur in up to 100% of patients but there 
are patients in which they occur only to a very minor extend (Parmar et al. 2013).  
Although rash can occur at minimum 3 days after start of erlotinib therapy, the median incidence 
of rash is the 8th day (Boeck et al. 2007, Saif et al. 2008). As skin rash occurs during both, 
monoclonal antibodies and small molecule inhibitors therapies, it is believed to be a class-related 
side effect. Notably, no difference between the histological pictures of rash in the two sub group 
has been reported. Rash occurs more frequently and severely in treatment with monoclonal 
antibodies compared to small-molecule inhibitors. Between the small molecule inhibitors, skin 
toxicity tends to be more severe with erlotinib compared to gefitinib (Togashi et al. 2011). Rash 
will ultimately fade out during one month after the end of EGFRI dosing (Li and Perez-Soler 2009).  
1.2.3.1 Characterization of rash 
Skin rash is referred to as folliculitis (Peuvrel et al. 2012) or more historically, acneiform eruption 
(Segaert and Van Cutsem 2005). It is often categorized according to National Cancer Institute 
Common Toxicity Criteria (NCI CTC). The grade of skin rash is found to be dose related (Peréz-
Soler and Saltz 2005, Robert et al. 2005, Roé et al. 2006, Segaert et al. 2009, Wolf et al. 2004). In 
addition, there is a well-confirmed correlation between overall survival and the grade of rash 
independent of which drug has been used (Peeters et al. 2009, Pérez-Soler et al. 2004, Peuvrel 
et al. 2012, Shepherd et al. 2005). 
Anatomically the rash is more frequent on the face, upper torso (V-shaped region), shoulders, 
and neck. Less frequently lower parts of the back, gluteal area, arm or legs are affected 
(Galimont-Collen et al. 2007, Peréz-Soler and Saltz 2005, Robert et al. 2005, Segaert et al. 2009). 
Thus, there may be an interaction of EGFRI induced skin rash with light exposure. Palms, soles 
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and mucosa, are always spared. (Agero et al. 2006, Baselga et al. 2002, Robert et al. 2005, Segaert 
et al. 2009). It has a papulo-pustular appearance; in addition, these lesions (papules and pustules) 
are monomorphic and aseptic. It is very rare that necrosis happens (Mass 2004, Segaert et al. 
2009). A useful distinction from acne is that comedones will never occur. The rash is occasionally 
painful (Boone et al. 2007, Burtness et al. 2009, Segaert and Van Cutsem 2005).  
 
1.3 Current data and hypotheses concerning the skin side effects 
1.3.1 Normal skin layers 
Because this is important for understanding of the adverse effects, a brief introduction into skin 
structure is given here. The human skin is composed of three major layers: epidermis, dermis and 
hypodermis. The epidermis itself consists of 4 layers: the basal, spinous, granular and the stratum 
corneum (Figure 1.3.1). Nearly 90% of the cells in epidermis are keratinocytes (other cell types in 
the skin include: fibroblasts and melanocytes). The basement membrane layer – placed between 
epidermis and dermis – is responsible for the generation of the epidermal layer (Candi et al. 
2005). This layer has the highest expression of the EGFR. Activation of this receptor plays a critical 
role during the development and migration of keratinocytes in the direction of surface. During 
this migration, the keratinocytes are differentiated and the expression of EGFR is lowered. The 
last layer – Stratum corneum – is formed after apoptosis of keratinocytes (Candi et al. 2005, 




Figure 1.3.1 Structure of normal epidermis and expression of EGFR in cells in this layer of skin. The EGFR is prominently expressed 
in the basal layer which is responsible for the generation of the epidermis. As the cells migrate to the more superficial layers, the 
EGFR expression is decreased. In the superficial layers of the epidermis there are keratohyalin granules which contributes to 
keratinization of the stratum corneum. The stratum corneum is mostly composed of dead keratinocytes, keratin fibers and filaggrin 
filaments. 
 
1.3.2 EGFR ligands 
EGFR can be activated upon the presence of several proteins such as EGF, transforming growth 
factor-α (TGFα), amphiregulin, heparin-binding EGF (HB-EGF) or epiregulin. All of these proteins 
contain a region with the amino acid sequence motif CX7CX(4-5)CX(10-13)CXCX8GXRC ; where Cs are 
cysteine, G is glycine, R is arginine and X could be any other amino acid. The characteristic feature 
of these molecules is a triple loop in structure, in which 6 cysteine amino acids make 3 intra-
molecular disulfide bridges. They are all EGFR specific ligands, meaning that they will not activate 
any other member of ERBB family (Hynes and Lane 2005). EGFR is activated by the auto and/or 
paracrine secretion of its ligands (by keratinocytes) such as amphiregulin which is the main ligand 







1.3.3 Pathophysiology of skin rash 
EGFR is typically expressed on the surface of keratinocytes of the basement membrane layer of 
the skin. It is involved in several vital functions in human skin including cell growth and 
proliferation, apoptosis evasion, migration and wound healing. Deterioration of any of these 
functions may result in a pathologic status which leads to rash. These physiologic roles are 
described in the following text. 
 
1.3.3.1 EGFR in cell growth and proliferation  
EGFR activation increases epidermal thickness by increasing the proliferation of the 
keratinocytes. Autocrine release of EGFR ligands was seen in keratinocytes both in vitro and in 
situ which can result in proliferation of these cells. Treatment of human keratinocytes derived 
from normal skin with EGFR inhibitors blocks the progression from the G1 to the S phase of the 
cell cycle and also inhibits DNA synthesis (Jost et al. 2000, Kobayashi et al. 1998).  
EGFR inhibition also causes the keratinocytes to express terminal differentiation gene markers 
such as KRT1 and KRT10 (keratin molecules which normally exist in outer layers of epidermis). On 
the other hand, removal of EGFR inhibition facilitates the down regulation of KRT1 and KRT10 
genes (Peus et al. 1997). In addition, EGF treatment downregulates the expression of other 
differentiation indicators such as profillaggrin and filaggrin and leads to nuclear retention 
(undifferentiated keratinocytes at the outer layer stratum corneum), in presence of extracellular 
matrix adhesion in skin reconstructs. Furthermore, premature hair keratinization was observed 
in EGFR-null mice (Threadgill et al. 1995).  
 
1.3.3.2 Apoptosis evasion 
Activation of EGFR facilitates the survival and evasion of programmed cell death in keratinocytes. 
Early apoptosis of keratinocytes will lead to thin epithelium and compromised barrier function of 
skin. On the other hand, neoplasia could develop if the keratinocytes evade the normal apoptosis. 
If the EGFR is inhibited by either small molecule tyrosine kinase inhibitors or by the anti-EGFR-
antibodies, keratinocytes will be prone to death when exposed to ultraviolet irradiation (Peus et 
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al. 1997) or oxidative stress (Wang et al. 2000) or when undergoing passaging in cell culture 
(Ravid et al. 2002). Apoptosis rate escalates up to fivefold between days 4 to 12 after EGFR 
inhibition. This time distance is in accordance with occurrence of rash in EGFR inhibitor (EGFRI) 
treated patients. Interestingly, treatment of fibroblasts and melanocytes with EGFRIs has shown 
no change in apoptosis rate, that leaves the keratinocytes as the primary suspect for rash after 
EGFR inhibition (Rodeck et al. 1997). In addition, several anti-apoptotic genes were 
downregulated after EGFR inhibition such as survivin also known as baculoviral IAP repeat 
containing 5 (BIRC5) and  B-cell lymphoma 2-associated athanogene (BAG1) (Lacouture 2006).  
 
1.3.3.3 Migration 
EGFR activation increases the migration of keratinocytes to the outer layers of the skin and leads 
to loss of intercellular attachments (Betson et al. 2002). By a similar mechanism, EGFR inhibition 
may also plays a role in decreasing tumor invasion and metastasis. Increased cell adhesion after 
EGFRI therapy could be explained by upregulation of cadherin–associated protein CTNND2 and 
the desmosomal cadherin DSG2. In addition EGFR signaling is required for activation of small 
GTPases which increase the stability of cadherin regulated intra-cellular contacts (Betson et al. 
2002).  
 
1.3.3.4 EGFR in wound healing  
EGF receptor activation by its ligands amphiregulin and HB-EGF appears to be vital to wound 
healing. These mentioned ligands, but not TGF-α, are strongly induced in cultures of human skin 
biopsy as a model of wound healing. Increased expression of these two ligands was also seen 
after disruption of mouse skin. HB-EGF is vastly upregulated in healing wounds from biopsies 
taken 6 days after skin graft removal (Stoll et al. 1997). In EGFR-null mice skin repair was 
diminished during first 3 days after intervention. An inflammatory process occurred in the 
wounds of these mice (infiltration of inflammatory cells such as neutrophils was observed). 
Wound healing in the medium which contains inflammatory cells would be hindered because of 
ongoing proteolytic processes during inflammation (Repertinger et al. 2004). However, systemic 
11 
 
EGFR inhibition therapy does not impair wound healing in human after full thickness dermal 
excision (Govindan et al. 2003).  
 
1.3.4 Role of inflammation in EGFR inhibition related skin toxicity 
EGFR inhibition by both small molecule TKIs or monoclonal antibodies may lead to the 
impairment of the mentioned vital EGFR functions such as proliferation, cell migration, wound 
healing, and differentiation. As a result, skin toxicity may occur caused by diminished skin 
integrity. On the other hand – possibly as a secondary effect consequent to the disrupted skin 
integrity – a moderate to severe inflammation is always present in the EGFRI associated skin 
toxicity.  
EGFR plays a key role in expression of cytokines in keratinocytes. EGFR activation is inversely 
associated with expression of chemokines and inflammatory molecules such as TNFα, regulated 
upon activation normal T cell expressed and presumably secreted protein (RANTES, also known 
as CCL5) and monocyte chemotactic protein-1 (MCP1 also known as CCL2). Exposure of epithelial 
cells to small molecule TKIs elevated the levels of other inflammatory molecules such as CXCL10, 
and T lymphocytes recruiting chemokines viz. CCL18, XCL1, CXCL9, fractaline and CCL3 (Mascia et 
al. 2003, Rodeck et al. 1997). Subsequently, the potential chemo-attraction by these molecules 
will be suppressed after EGFR blockage. EGFR inhibition also stabilizes the chemokine molecules 
(Pastore et al. 2005). 
The pro-inflammatory transcription factor NFKappaB is upregulated after treatment of cervical 
epithelial cells in an organo-typic culture with EGFRIs (Woodworth et al. 2005). Furthermore, 
local application of HuMab-10F8 (IL-8 neutralizing antibody) has reversed the skin rash occurred 





1.4 Possible candidate genes in EGFR inhibition related skin rash 
As was outlined above, skin rash is believed to be a class effect of all EGFR inhibitors. We 
hypothesized that the inhibition of the EGFR pathways is the reason of rash and therefore we 
analyzed several important proteins from the EGFR pathways. In addition, inflammation is 
considered to play an important role in formation of EGFR inhibitor induced rash. The 
transcription factor NFκB is known to stimulate expression of proinflammatory genes and was 
shown to be upregulated after EGFR inhibition (Woodworth et al. 2005). Furthermore, an 
antibody neutralizing IL-8 has been shown to be effectively reducing and reversing the rash 
development. Considering the presented facts we have decided to analyze variation in the EGFR 
pathways and in selected pro-inflammatory pathways in our study sample. For a better 
understanding of these molecules a short description is presented in the following text. 
Upon stimulation of EGFR two major pathways are activated. These are the Ras-MAPK and the 
PI3K-Akt pathways. Activation of the EGFR via its ligands results in phosphorylation of tyrosine 
residues of intracellular protein regions of the EGFR. The phosphotyrosine residue has high 
affinity for binding to adaptor molecules which after activation, mediate the binding of GTP to 
Ras and results in its activation (Kolch 2000, Stokoe et al. 1994). 
 
1.4.1 Ras-MAPK pathway 
The Ras-MAPK pathway may be activated via the EGFR (Figure 1.4.1). MAPK stands for mitogen-
activated protein kinase. The first molecule in this pathway is Ras which is a small molecule 
GTPase. The Ras family has four members, N-Ras, H-Ras, K-Ras4A and K-Ras4B which the last two 
are the result of alternative splicing in KRAS gene. Conformational changes that occur after 
binding of GTP to Ras subsequently activates the Raf protein (Barbacid 1987, Jancík et al. 2010, 
Vakiani and Solit 2011, Wennerberg et al. 2005).  
Raf (also known as mitogen-activated protein kinase kinase kinase (MAPKKK), meaning that it 
phosphorylates MAPKK which in turn phosphorylates MAPK or ERK) is a serine/threonine kinase. 
Ras-GTP stabilizes Raf by binding to its N terminal and phosphorylating it; besides, it recruits Raf 
to the membrane. As a result, the C terminal is now made free through the conformational 
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changes that occur; and therefore can act as a kinase. Since we were not assured by the literature 
that which of the three raf proteins are relevant in keratinocytes, we analyzed all three, RAF1, 
ARAF and BRAF. All three kinases have a very similar structure. Raf then continues the kinase 
cascade by activating MEK (Stokoe et al. 1994, Vakiani and Solit 2011).  
 
Figure 1.4.1 Ras-MAPK pathway. The underlined molecules are investigated in current study. EGFR, epidermal growth factor 
receptor; GRB2, growth factor receptor-bound protein 2; SOS, son of sevenless; RAS, rat sarcoma; RAF, v-raf-1 murine leukemia 
viral oncogene homolog; MEK , MAPK/ERK kinase; ERK, extracellular signal-regulated kinase; RSK, Ribosomal s6 kinase; c- Fos, 
homolog of the retroviral oncogene v-fos. Names of the genes analyzed corresponding to each protein is shown in boxes. 
 
MEK, also known as MAPKK, is a dual specific kinase – targeting tyrosine and threonine – which 
is normally inactive. Raf causes a conformational change in MEK and activates it. This is because 
it phosphorylates ERK which is also known as MAPK. Two isoforms of MEK have been identified; 
MEK1 (MAP2K1) and MEK2 (MAP2K2). MEK1 and MEK2 activate ERK1 (MAPK1) and ERK2 
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(MAPK3), respectively (Roskoski 2012).  
The ERK proteins (extracellular signal-regulated kinase) are serine/threonine kinases, which after 
being phosphorylated, can phosphorylate its cytoplasmic or nuclear substrates. After being 
activated, ERK migrates to the nucleus and increases expression of transcription factors or 
immediate early response genes such as C-FOS and C-MYC. The nuclear transcription factor 
targets of ERK1/2, play a major role in inducing the expression of the late-response genes that 
boost cell survival, cell division, and cell motility. This is believed to be the major result of EGFR 
stimulation in MAPK pathway (Eferl and Wagner 2003, Murphy et al. 2002, Okazaki and Sagata 
1995). 
On the other hand, there are more than 50 cytoplasmic substrates for ERK including: RSK family 
protein kinases, phosphoprotein phosphatases, cytoskeletal proteins, apoptotic proteins, and 
regulatory and signaling molecules. Ribosomal S6 kinase (RSK) proteins are 90 kDa 
serine/threonine kinases that control cell growth, motility, proliferation, and survival. ERK1/2 
directly activates RSK enzymes when it is stimulated by growth factors, polypeptide hormones, 
neurotransmitters, or chemokines. RSKs are key components downstream from the Ras-MAPK 
signaling cascade which phosphorylate 35 proteins. In different types of cancer RSK1 and RSK2 
are up-regulated that suggests their involvement in oncogenesis (Anjum and Blenis 2008, 
Carriere et al. 2008, Ramos 2008). 
 
1.4.2 PI3K-Akt pathway 
Another pathway downstream of EGFR is PI3K-Akt pathway. Many of physiologic roles of EGFR 
are mediated through this pathway (Figure 1.4.2). EGFR binds to and stimulates 
Phosphoinositide-3-kinase regulatory subunit of Phosphatidylinositol 3 kinases (PI3Ks) via an 
adaptor proteins, such as IRS-1. PI3Ks are membrane-anchored proteins which facilitate the 
transfer of a phosphate group of ATP to phosphoinositides. PI3Ks are categorized into four 
classes: IA, IB, II, III. Class IA interacts with receptor tyrosine kinases and are heterodimers 
consisting of regulatory and catalytic subunits. Activated PI3K catalyzes the phosphorylation of 
phosphatidylinositol 3,4-bisphophate (PIP2) to phosphatidylinositol 3,4,5-tiphosphate (PIP3) 
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(Fresno Vara et al. 2004, Rameh and Cantley 1999, Volinia et al. 1995). 
Tumor suppressor phosphatase and tensin homolog (PTEN) can undo the action of PI3Ks by 
conversion of PIP3 to PIP2 (de-phosphorylation of PIP3) which results in inhibition of the PI3K-
Akt pathway (Li et al. 1997, Salmena et al. 2008).  
 
Figure 1.4.2 PI3K-Akt pathway. The underlined molecules are investigated in current study. The large bright-blue arrow indicates 
that the double inhibition finally results in an activation of the mTOR pathway. IRS-1, Insulin receptor substrate 1; PI3K, 
phosphatidylinositol 3-kinase; PIP2, phosphatidylinositol biphosphate; AKT, v-akt murine thymoma viral oncogene homolog; TSC, 
tuberous sclerosis complex; Rheb, Ras homolog enriched in brain; MTOR, mechanistic target of rapamycin;. All the factors which 
have been resequenced in the present study are underlined. Names of the genes analyzed corresponding to each protein is shown 
in boxes. 
 
Akt protein – a serine/threonine kinase – translocates to the membrane and binds to PIP3 
molecule. This positioning then enables the phosphatidylinositol-dependent kinase 1 (PDK-1) to 
phosphorylate Akt. Phosphorylated Akt (pAkt) directly phosphorylates proteins involved in 
16 
 
avoiding apoptosis, survival and cell growth signaling, including BIM, BAD, MDM2, FOXO, 
procaspase‐9, PED (an inhibitor of caspase 3), ASK1, PRAS40 and TSC2 (Bellacosa et al. 2005, 
Franke 2008). Akt is involved in several cellular processes via interacting with mechanistic target 
of rapamycin (mTOR) and NFkB complexes.  
MTOR is a protein kinase of PI3K related kinase family. This kinase plays its physiological roles via 
interactions with other molecules in forms of two complexes named mTOR complex 1 (mTORC1) 
and 2 (mTORC2) (Laplante and Sabatini 2012). Akt, ERK, and RSK1 kinases directly phosphorylate 
TSC1/TSC2 proteins to inactivate them. TSC1/2 are GTPase activating proteins that convert the 
Ras homolog enriched in brain (Rheb) GTPase from GTP-bound state to GDP-bound state. 
Inhibition of TSC proteins results in an increase of GTP-bound form of Rheb and subsequently 
induces the mTORC1’s kinase activity. The process in which mTORC2 is involved is less 
understood – specially its upstream activation –; however, it is known that it directly stimulates 
Akt by phosphorylating it. Activation of Akt results in evading apoptosis and cell growth via MTOR 
complexes. Major role of mTORC1 is controlling the protein synthesis. mTORC1 serves this role 
by phosphorylates the translational regulators eukaryotic translation initiation factor 4E (eIF4E) 
and S6 kinase 1 (S6K1 a member or RSK family proteins) (Laplante and Sabatini 2012).  
 
1.4.3 Inflammatory genes involved 
The transcription factor NFκB is known to stimulate expression of proinflammatory genes and is 
shown to be upregulated after EGFR inhibition (Woodworth et al. 2005). NFκB or “Nuclear factor 
kappa-light-chain-enhancer of activated B cells” super family of transcription factors in mammals 
includes the following five transcription factors: p50 (NF-κB1/p105), p52 (NF-κB2/9100), RelA 
(p65), RelB and c-Rel, which perform their function in dimer form. Homo or hetero dimers of NF-
κB transcription factor recognize κB-sites – 9 to 10 base pair DNA regulatory sites – and as a result 
stimulate the specific target gene expression (Gilmore and Herscovitch 2006, Hoffmann et al. 
2006, Moynagh 2005).  
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Furthermore, in 2012 Bangsgaard’s group surveyed the hypothesis that neutrophilic infiltration 
in rash affected areas is attracted by IL-8. Firstly they induced rash by local injection of 
zalutumumab (an EGFR inhibitor). Afterwards they applied a human IL-8 neutralizing antibody 
(HuMab-10F8) locally and reduced the rash. Therefore they concluded that antibodies 
neutralizing IL-8 may effectively reduce and reverse the rash development. IL8 transcription is 
also known to be mediated by NFκB (Bangsgaard et al. 2012) (Figure 1.4.3). An overview of stated 
genes which are involved in downstream signaling of EGFR and hypothetically are responsible for 
rash development is displayed in Figure 1.4.4.  
 
Figure 1.4.3 Inflammatory genes involved in pathogenesis of rash. NFκB, Nuclear factor kappa B, IL8, Interleukin 8;.CXCR, CXC 
chemokine receptor (IL8 receptors); IL1, interleukin 1; TNF-α, tumor necrosis factor alpha. All the factors which have been 








1.5 Known facts about genomic variation in relation to skin side effects of EFGR 
blocking 
Skin toxicity is believed to be a class side effect of EGFRIs, meaning that it can be caused by EGFR 
inhibition independent of the drug type (small molecule TKIs or monoclonal antibodies). The skin 
toxicity does not occur in all patients. This fact leaves germline genetic variations in EGFR and its 
downstream signaling pathway as the primary suspects for this difference. Several studies have 
tested this hypothesis. 
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In 2009 Klinghammer et al. studied EGFR gene polymorphisms in 51 patients with recurrent or 
metastatic head and neck squamous cell carcinoma (HNSCC) in a single arm phase II study of 
cetuximab/docetaxel. Forty one percent of their patients had skin toxicity as a treatment side 
effect. Two variations in EGFR gene were analyzed in relation to skin toxicity in their study. Firstly 
a variation of arginine to lysine in the 521th amino acid position of EGFR gene (rs2227983 also 
known as EGFR R497K): allele G to A change at DNA level causes the amino acid change. The G/G 
genotype was significantly associated with appearance of skin rash in these patients. They have 
dichotomized patients as follows: patients with rash level 0 and 1 in one group and patients with 
level 2 and 3 in another group. A dominant model (having or not having a minor allele) 
categorization was used for analysis. Moreover, a CA microsatellite repeat polymorphism 
(rs11568315) in intron 1 of EGFR gene was surveyed in this study. They have analyzed the 
correlation between a short (less than or equal to 16) or long (more than 16) CA repeat in the 
patients. No significant association was found between rs11568315 and skin rash (Klinghammer 
et al. 2010).  
However this association was not confirmed in several other studies. In 2010, Giovannetti et al. 
studied the correlation between EGFR or AKT1 polymorphisms and skin toxicity in 96 NSCLC 
patients treated with Gefitinib. The EGFR -191 C/A, EGFR -216 G/T, EGFR R497K, and rs11568315 
CA repeat polymorphisms were analyzed, as well as the AKT1 polymorphisms rs3730350 and 
rs1130233 were analyzed. They also categorized the patients according to skin toxicity into grade 
0-1 and grade 2-3 groups. None of the other studied polymorphisms were significantly associated 
to skin rash (Giovannetti et al. 2010). In 2007, Li et al. surveyed the EGFR polymorphisms -191 
C/A, -216 G/T, R497K, and rs11568315 CA repeat in NSCLC patient treated with Gefitinib. The-
216 G/T was significantly associated with presence of skin toxicity of grade equal to or more than 
1. However, the EGFR -191C/A, intron 1 CA dinucleotide repeat polymorphism, or the R497K SNPs 
had no association with skin rash manifestation (Liu et al. 2008).  
In this regard also McKibbin et al. analyzed the EGFR polymorphisms in combined data from five 
pediatric clinical trials with gefitinib. They have found an association between EGFR -216 G/T and 
grade 1 or more skin rash in a recessive model. Intron 1 CA dinucleotide repeat polymorphism, 
the -191C/A, or R497K did not have a significant association with skin rash (McKibbin et al. 2010).  
20 
 
Another group has surveyed skin toxicity in 52 patients receiving Gefitinib as a first line therapy 
of NSCLC. They have found an association between short CA repeat alleles and grade 2-3 skin 
rash. Other 3 frequently studied EGFR polymorphisms (-191 C/A, -216 G/T, R497K) had no 
significant association to skin rash (Huang et al. 2009). In another study on 175 NSCLC patients 
receiving gefitinib, EGFR -191 C/A, EGFR -216 G/T, and rs11568315 CA repeat were not found to 
be significantly associated with skin rash (Gregorc et al. 2008).  
EGFR polymorphisms were also analyzed in erlotinib therapies. In a prospective study of 80 NSCLC 
patients, Rudin et al. have studied EGFR polymorphism in relation to erlotinib skin toxicity. None 
of EGFR -191 C/A, EGFR -216 G/T, EGFR R497K, and rs11568315 CA repeat were associated with 
skin rash. They have as well studies a number of SNPs in CYP3A4, CYP3A5, ABCG2 genes (refer to 
Table 1.5.1). Only ABCG2 16702 G/G genotype was associated with skin rash (Rudin et al. 2008).  
EGFR R497K or rs2227983 is an arginine to lysine substitution at the 521th amino acid of EGFR 
protein (at the time of this functional study they believed that the substitution is at 497 position 
therefore historically this variation is called R497K). To identify the molecular mechanism in 
which the rs2227983 is involved, Moriai et al. expressed the wildtype and variant EGFR in Chinese 
hamster ovary (CHO) cells and compared the binding of EGF and TGF-α. Both receptors have 
shown two (a high and a low) affinity sites for EGF; however, the variant receptor had no high 
affinity site for TGF-α but only a low affinity site for TGF-α. The authors also displayed that the 
cells expressing EGFR R497K had decreased growth response (investigated by MTT assay) to EGF 
and TGF-α; and decreased stimulation of FOS, JUN and Myc. Therefore, they hypothesized that 
substitution of this residue in an extracellular domain modulates the phosphorylation of the 
intracellular domain of EGFR (Moriai et al. 1994).  
Another group investigated the impact of EGFR R497K on EGFR phosphorylation and Myc 
activation in colorectal cancer tissue. They stained the tumor tissue segments with anti-
phosphorylated EGFR and anti-c-Myc antibodies. They have observed a marked decrease in EGFR 




Table 1.5.1 Summary of polymorphisms studied in EGFR gene by different studies and their association with skin rash. Many of 














No difference (Giovannetti et al. 2010) (Liu et al. 2008) 
(McKibbin et al. 2010) (Huang et al. 






T allele was associated 
with skin rash 





T/T genotype associated 
with skin rash  





No difference (Giovannetti et al. 2010) (Huang et al. 
2009) (Gregorc et al. 2008) (Rudin et al. 
2008) 
EGFR Exon 13 rs2227983 
(R497K) 
G/G genotype associated 
with skin rash 
(Klinghammer et al. 2010)  
EGFR Exon 13 rs2227983 
(R497K) 
A/A genotype associated 
with skin rash (G/A 
genotype with absence of 
skin rash) 
(Parmar et al. 2013) 
EGFR Exon 13 rs2227983 
(R497K) 
No difference (Giovannetti et al. 2010) (Liu et al. 2008) 
(McKibbin et al. 2010) (Huang et al. 
2009) (Gregorc et al. 2008) (Rudin et al. 
2008) 
EGFR Intron 1 rs11568315 
(intron 1 CA 
repeat) 
Shorter alleles were 
associated with skin rash 
(Huang et al. 2009) 
EGFR Intron 1 rs11568315 
(intron 1 CA 
repeat) 
No difference (Klinghammer et al. 2010) (Giovannetti 
et al. 2010) (McKibbin et al. 2010) 
(Gregorc et al. 2008) (Rudin et al. 2008) 
AKT1 Gene 
upstream 
rs3730350  No difference (Giovannetti et al. 2010) 












AKT1 Intron 5 rs3001371 No difference (Parmar et al. 2013) 
AKT1 Intron 3 rs2498794 No difference (Parmar et al. 2013) 





No difference (Rudin et al. 2008) 
CYP3A5 Intron 3 rs776746 
(CYP3A5*3) 
No difference (Rudin et al. 2008) 
ABCG2 Exon 5 rs2231142 
(421 C/A) 
No difference (Rudin et al. 2008) 
ABCG2 Exon 2 rs2231137 
(34 G/A) 
No difference (Rudin et al. 2008) 
ABCG2 Intron 1 rs2622604 
(1143 C/T) 
No difference (Rudin et al. 2008) 
ABCG2 Intron 13 No_rs 
(16702 G/A) 
G/G genotype was 
associated with skin rash 










No difference (Rudin et al. 2008) 
PIK3CA Gene 
upstream 
rs9831234 No difference (Parmar et al. 2013) 
PIK3CA Intron 1 rs2699905 No difference (Parmar et al. 2013) 
PIK3CA Intron 1 rs6443624 No difference (Parmar et al. 2013) 
PIK3CA Intron 1 rs2677760 No difference (Parmar et al. 2013) 
PIK3CA Intron 9 rs2459693 T/C genotype was 
associated with skin rash 
(Parmar et al. 2013) 
No_rs: no rs number assigned. 
 
In 2011 Parmar et al. published the analysis of a number of EGFR, AKT1, and PIK3CA 
polymorphisms (refer to Table 1.5.1) in the same sample population as the present study in 
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association with skin rash. They analyzed EGFR -191 C/A, EGFR -216 G/T, EGFR R497K, and 
rs11568315 CA repeat and found an association between the R497K polymorphism with skin 
rash. Except for PIK3CA rs2459693, which T/C genotype was associated with skin rash; other 
polymorphisms were not significantly associated with skin rash (Parmar et al. 2013). 
As summarized in the Table 1.5.1, few studies could reproduce the presumed consequence of 
EGFR polymorphisms on skin toxicity manifestation. The functional in vitro effects were not 
reproduced in the clinical studies. As a conclusion from the introductory review, the data 
regarding the effect of polymorphisms in the EGFR pathway on skin rash are very controversial 
and a systematic study to analyze a wider spectrum of genetic variations is needed. 
 
1.6 Genetic variations and genetic testing 
1.6.1 Human genome and its variations 
DNA variations are responsible for many variations observed among human populations such as 
disease susceptibility and the propensity to positive or negative effects of xenobiotics including 
drugs.  
The most common human genetic variation is the single nucleotide polymorphism (SNP) that 
accounts for 88% of isolated genetic variations (Levy et al. 2007). SNP is referred to as a single-
nucleotide variation in a genetic sequence; a common form of variation in the human genome 
(Feero et al. 2010). These variations occur commonly within a population (e.g.at a rate of 1%). 
SNPs occur on average at a rate of 5 in 1000 bp and according to recent studies about 15 million 
of them are found (Genomes Project et al. 2010, Mills et al. 2011). An average individual is 
estimated to harbor 3.3 million SNPs (Shen et al. 2013).  
It is probably necessary to define some genetic terms for the better understanding of the 
following text. An allele is “one of two or more versions of a genetic sequence at a particular 
location in the genome” (Feero et al. 2010). Haplotype is “a set of DNA variations, or 
polymorphisms, that tend to be inherited together. A haplotype can refer to a combination of 
alleles or to a set of single-nucleotide polymorphisms found on the same chromosome” (Feero 
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et al. 2010). Haplotypes can reside in one locus, or several loci. Using haplotypes has made it 
possible to reduce the number of SNPs tested for examining the genome; as a SNP (tagging SNP) 
can be representative of other SNPs in the same haplotype.  
Genetic variations can occur in form of loss or gain of genomic material from 1 kilobase to several 
megabases in size, by deletions, duplications, inversions, and translocations. Copy number 
variation (CNV) is “a common variation in this category. CNV is defined as the variation from one 
person to the next in the number of copies of a particular gene or DNA sequence” (Feero et al. 
2010). By the completion of the Human Genome Project, CNV was identified as a widespread and 
common phenomenon among humans (Sebat et al. 2004). Approximately 0.4% of the genome of 
unrelated people differ typically with respect to copy number (Kidd et al. 2008).  
 
1.6.2 Importance of genetic testing  
Genetic variations may make the individuals prone to acquired diseases. Among these diseases, 
cancers are of bold significance. Genetic variations cause a susceptibility to carcinogens in the 
environment. Many of these variations affect drug metabolizing enzymes and therefore cause 
various responses to drugs or xenobiotics. Examples are mentioned in following text. 
 
1.6.2.1 Kras variations 
Proto-oncogene Ras is a GTPase protein which, upon activation, stimulates many cellular 
functions especially cell growth and proliferation. In normal situations Ras function is strongly 
regulated. Ras is frequently mutated in human cancers. As an example, Kras mutations are found 
in 90% of pancreatic tumors. Many single mutations have been found in RAS gene at codons 12, 
13 or 61 which contribute to hyperproliferation in tumors (Quinlan and Settleman 2009). These 
mutations result in ever-active state of this protein even without upstream stimulations. The 




1.6.2.2 Variations in metabolic enzymes 
The metabolism of xenobiotics or foreign biologic substances is vital for human body for 
detoxifying and excretion of these substrates. This metabolism is commonly categorized in three 
phases: modification, conjugation, and excretion (Omiecinski et al. 2011). Phase I or also known 
as modification is the addition of functional groups such as -OH, -SH, -NH2 or –COOH to 
xenobiotics. In Phase II (conjugation), xenobiotics are conjugated with charged species such as 
glutathione, sulfate, glycine, or glucuronic acid. Glutathione S-transferases (GSTs) as an example 
of phase II enzymes are involved in inactivation of oxidative metabolites or carcinogenic 
compounds. Moreover they may play a role in activation of DNA repair enzymes (Pinarbasi et al. 
2005). GSTM1 and GSTT1 polymorphisms have been reported to be associated with lung cancer 
(Hosgood et al. 2007) and prostate cancer (Ashtiani et al. 2011). Finally in phase III (exceretion), 
some xenobiotics may undergo further modification and be excreted. One example for phase III 
metabolism is the function of membrane transporters to shuttle drugs and other xenobiotics 
across cellular membranes (Omiecinski et al. 2011). 
 
1.6.2.3 Glucose 6 phosphate dehydrogenase 
The deficiency of this enzyme was found when 10% of African American soldiers were presented 
with hemolysis after treatment with primaquine (an antimalarial drug). This enzyme is 
responsible for performing a reaction which produces NADPH co-enzyme (a reducing agent). 
NADPH provides the cells with reduced glutathione which in turn clears the free radicals that 
cause oxidative damage. This oxidative damage causes hemolysis in red blood cells. Decreased 
glutathione level makes the cells prone to hemolysis in case of administration of certain drugs 
such as several antimalarial drugs (Schuurman et al. 2009). Nowadays G6PD deficiency or Favism 
disease is a well know disorder and to date more than 150 causal mutations have been identified 




1.6.3 Development of methods for analysis of human genomic variations  
Considering the described roles of genetic variations, including their possible roles in contributing 
to disease prevention, and individualized and optimized choice of drug, the analysis of human 
genome is substantially vital.  
Methods in genotype analysis have undergone huge advancements in recent 30 years. 
Genotyping by using the restriction site of endonuclease enzymes was historically one of the first 
methods used. Restriction endonucleases identify a specific sequence and cut DNA at this site. 
This specificity had been used to identify the genetic variations. Restriction activity has been 
reported in 1952 for the first time (Luria and Human 1952). Later on it has been shown to be 
promising in identifying human beta-globin protein genetic variations (Kan and Dozy 1978).  
Elucidation of the entire human genome strongly depended on methods to reveal the DNA 
sequence. One of the first methods was the Maxam-Gilbert method which was not widely used 
later in DNA sequencing because of its complexity (Maxam and Gilbert 1977). However this 
method has led to development of Methylation Interference Assay for studying DNA protein 
interaction (Carey and Smale 2007). In 1977 Sanger et al. reported a new method for determining 
nucleotide sequence. Sanger and colleagues used dideoxynucleoside triphosphates for 
termination of polymerase chain reaction (PCR) and then categorized resulting segments 
according to which of the dideoxynucleoside triphosphates were used (ddATP, ddGTP, ddCTP, or 
ddTTP) (along with three normal nucleosides). Segments were then typically visualized on 12% 
acrylamide gels with autoradiography. As a result considering the order of segments by size, 
determining the exact nucleotide sequence was facilitated (Sanger et al. 1977). This method has 
been the most widely used method for analysis of genetic variation for 25 years after its 
invention. 
These approaches have made it possible to test the candidate gene variations in association with 
the specified diseases. Despite the efforts and resources consumed on this approach in the past, 
only small number of associations has been confirmed. Consequently, the molecular genetic basis 
of common diseases is still poorly understood (Hirschhorn et al. 2002). In recent years using 
genome wide association studies (GWAS), the entire genome was scrutinized to find associations 
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with diseases. GWAS have successfully found over 4000 common variants in which had 
associations with 200 common complex diseases (Johnson and O'Donnell 2009, Manolio et al. 
2008, Visscher et al. 2012, Wellcome Trust Case Control 2007). These variants could have never 
been identified using the candidate-gene approach, as even several were placed in some gene-
depleted regions of genome. But still for most common chronic diseases the known variants do 
explain only a minor fraction of the variation in disease risk between individuals. One of the 
exceptions is the association of a common variation in the complement factor H gene (CFH) with 
age-related macular degeneration (Klein et al. 2005). Other successful examples are locus 9p21.3 
variants and coronary artery disease and locus 8q24 with cancer (Wellcome Trust Case Control 
2007). Up to the present time hundreds of GWAS were performed. Although many were 
successful; still they do not address a large fraction of disease burden of diseases in population 
(Schork et al. 2009).  
As the GWAS analyze the whole genome regardless of any hypothesis which assumes a 
pathophysiologic role of specific genes in a common disorder, they are also called “hypothesis-
free”. This approach has the advantage of finding novel underlying mechanisms for diseases. 
Most GWAS analyze the SNPs with the frequency of more than 5% and therefore identifying rare 
variants is not possible. Consequently the application of GWAS is restricted to discovery of 
common variants in association to diseases, which fits into the common disease/common 
variants (CDCV) hypothesis (Lander 1996). On the other hand, most functional or deleterious 
variants are reported to have a frequency of <1% (Kitsios and Zintzaras 2009). This makes the 
GWAS to be unable to identify rare variants and make them inappropriate for testing Common 
disease/rare variants (CDRV) hypotheses according to be common disease are caused by multiple 
rare variants. Evidence on CDRV hypothesis comes from studies investigating diseases such as 
cystic fibrosis and BRCA1/2 breast cancer, in which hundreds of rare but disease causing 
variations have been found (Bobadilla et al. 2002, Iyengar and Elston 2007).  
After introduction of next generation sequencing also termed as deep sequencing or massively 
parallel sequencing, analysis of rare variants was made possible. This technology has made DNA 
sequencing fast, cost-effective for large targets, and more accurate (e.g. in case of finding rare 
somatic variations or viral mutations). There are different technologies which the two most 
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frequently used ones are sequencing-by-synthesis and semi-conductor based sequencing. These 
technologies facilitated a broad spectrum of applications which can be categorized into DNA, 
RNA and epigenetic applications. 
DNA sequencing applications include whole genome sequencing (WGS), whole exome 
sequencing, and targeted sequencing. WGS has made it possible to identify every variation in a 
patient’s genome resulting in a detailed catalog of rare genetic variants. As an example 1000 
genomes project has largely contributed to this catalog (Genomes Project et al. 2010, Kaiser 
2008). However WGS seems to be a very powerful tool for analysis of genomic variations; it is 
still very expensive and unaffordable to be used for large samples. Whole exome sequencing on 
the other hand is a more affordable approach which covers all functional variations. Studies using 
exome sequencing have so far identified causal mutations in several cancers and genetic diseases 
(Agrawal et al. 2011, Wu et al. 2012, Yan et al. 2011). A more flexible approach is targeted re-
sequencing which not only can be used as a primary approach but also can be used as a 
confirmatory study with larger sample size for variants identified by whole genome sequencing 
(Mamanova et al. 2010).  
 
1.6.4 Massively parallel sequencing or deep sequencing 
High-throughput sequencing technologies have made the sequencing of genome faster, 
affordable and even more precise. While to this date several high-throughput technologies are 
introduced, the common quality of all these methods is parallelizing the sequencing reactions. 
Three platforms for deep sequencing are commonly used at present: Roche/454, Illumina, and 
Ion torrent (Mardis 2013). In the following text the sequencing-by-synthesis (Illumina TM) and 
semi-conductor based (Ion torrent TM) sequencing will be explained.  
 
1.6.4.1 Sequencing-by-synthesis or Illumina sequencing 
In sequencing-by-synthesis also termed as Illumina TM sequencing approach genomic DNA is 
fragmented and then ligated to specific adaptors. In the next step a flow cell – a glass 
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microfabricated device – which allows the genomic DNA fragments to be amplified on its surface 
is used. This amplification is called bridge amplification. In this process single stranded adaptor 
ligated DNA is attached to the surface of the flow cell by the adaptor complementary sequences 
which are already fixed on the surface. Then one cycle of the amplification will be performed 
using this complementary sequence. The DNA is afterwards denatured and each strand which is 
attached to a complimentary fixed sequence is straightened (does not have the bridge form). The 
free adaptor sequence of each fragment is then attached to the complementary sequence fixed 
on the flow cell surface that forms a bridged DNA molecule. Several cycles are performed to 
amplify the template molecule. 
For sequencing, in each flow the machine adds all four nucleotides simultaneously to the flow 
cell along with the DNA polymerase. The nucleotides contain a fluorescent label which is unique 
for each base and a 3’-OH blocking group. The blocking group prevents the addition of more than 
one nucleotide per reaction. After addition of each base an imaging process will be performed to 
record that which nucleotide is added in the performed reaction. Subsequently, the 3’-OH 
blocking group including the fluorescent dye  is chemically removed, that allows another 
nucleotide to be attached in the next sequencing flow. Finally the data will be analyzed with a 
base-calling algorithm which assigns sequences and corresponding quality values to each read 
(Bentley et al. 2008).  
 
1.6.4.2 Semi-conductor based or Ion torrent TM sequencing 
In this platform which is explained in details in the methods section, DNA fragmentation of whole 
genomic DNA is performed as the first step. The fragments then will be ligated to specific adaptor. 
These adaptors assist the amplification of genomic DNA and also allow the user to barcode 
different DNA samples from different subjects or tissues. Then an amplification step will be 
performed using emulsion PCR. In this process a DNA molecule is amplified inside an oil 
microvesicle in attachment to a specific beads or spheres (Ion Sphere Particle TM, ISP). These ISPs 
already contain specific sequences complimentary to adaptor sequences and the primers used 
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for amplification at this step. Afterwards sequencing primers are added to ISPs along with the 
DNA polymerase.  
The ISPs are then loaded on a sequencing chip. A sequencing chip contains a million or more of 
microscopic wells depending on the chip type. These wells are the units of sequencing reaction. 
Each ISP is then seeded in each well. Nucleotides are then added one by one to the sequencing 
chip and if they are complementary to the template a PH change will occur. The chip senses this 
PH change and records it in association with the type of added nucleotide. Then this data will be 
analyzed (base-calling and quality assessment by the sever computer attached to the sequencing 
machine (Mardis 2013).  
 
1.7 Hypotheses and a short work plan of the thesis 
As described above there is a variation in the individual propensity to EGFR inhibitor induced skin 
rash and it appears to be very likely that genetic variations in proteins from the EGFR-signaling 
pathway play a role in this variation. Besides the EGFR pathway the EGFRI induced skin reaction 
is apparently highly inflammatory and genetic variations in cytokines, chemokines and their 
receptors may also be relevant. 
We had the possibility to study 126 samples from patients who had been treated with EGFR 
inhibitors and in whom the adverse effects were characterized in detail. To comprehensively 
analyze genomic variations we have used deep sequencing on Ion Torrent TM system.  
Following tasks were essential to the workplan: 
• Definition of the most plausible candidate genes based on a molecular review of the 
EGFR pathway and based on prior data on genomic variants associated with skin 
rash 
• Bioinformatic selection of the genomic segments to be re-sequenced 
• Preparation of DNA samples to be compatible with DNA sequencing 
• Performing re-sequencing on the Ion Torrent TM system  
• Bioinformatic filtering of reliable versus unreliable variants 
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• Bioinformatic analysis of the reliable variants concerning their presumed 
functionality 
• Statistical analysis of the variants found in relation to skin rash and as additional 
exploratory analysis also in relation to diarrhea (another frequent side effect) and in 
relation to overall survival. 
This project should contribute to a better understanding of EGFRI induced skin rash and possibly 
to the development of molecular biomarkers allowing to select individually efficient but better 




2 Methods  
2.1 Clinical study design and definition of the phenotypes 
To analyze the genetic variation in EGFR pathway, patients receiving EGFR inhibitors were 
enrolled to this study. Before the enrollment, written informed consent concerning 
pharmacogenomics analysis was obtained from all participating subjects. Inclusion criteria were 
histologically confirmed cancer disease and first-time treatment with an EGFRI (either 
monoclonal antibody or small molecule TKI). Grade of skin rash was evaluated using National 
Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0 (NCI CTCAE v3.0). 
This criteria is shown in Table 1.6.4.1 .The study protocol was verified by the ethical review boards 
of the University Ulm and the LMU Munich. Patients were recruited from the stated medical 
centers. 
Table 2.1.1 Grading of rash according to toxicity criteria of the National Cancer Institute (NCI CTCAE) version 3.0. 
Grade Features 
1 Macular or papular eruption or erythema without associated symptoms 
2 Macular or papular eruption or erythema with pruritus or other associated 
symptoms; localized desquamation or other lesions covering <50% of body 
surface area (BSA) 
3 Severe, generalized erythroderma or macular, papular or vesicular eruption; 
desquamation covering ≥50% BSA 
4 Generalized exfoliative, ulcerative, or bullous dermatitis 
 
Overall survival (OS) was described as the duration (in days) from treatment start to the date of 
death. Alive patients at the last available follow-up were censored at the last date they were 
known to be alive. Follow up was performed for the duration of 360 days.  
 
2.2 Target region criteria  
Thirty genes were targeted for resequencing. The whole EGFR gene along with 2000 bp of its 
promoter region was one of the targets. The total size of these regions was 196300 base pairs. 
For the remaining 29 other responsible genes, the exons along with 500 bp of promoter region 
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were selected. These 29 genes are namely: AKT (AKT1, AKT2, AKT3), RAF (ARAF, BRAF, RAF1), RAS 
(HRAS, KRAS, NRAS), ERK (MAPK3, MAPK1), MEK (MAP2K1, MAP2K2), MTOR (MTOR) NFKB 
(NFKB1, NFKB2, REL, RELA, RELB), S6K (RPS6KB1, RPS6KB1), PI3K (PIC3CA, PIK3CB, PIK3R1, 
PIK3R2), PTEN (PTEN), Interleukin 8 (IL8) and its receptors (CXCR1, CXCR2) (Table 2.2.1). Total size 
of the sequencing target is 382400 basepairs. 
 Table 2.2.1 The selected genes and their corresponding size. The entire EGFR gene along with 2000 bp of its promoter region 
(total 196300 bp) was also sequenced which is not shown in this table. 




Region size in 
bp 
Gene name Region size in 
bp 
PI3K/Akt AKT1  8423 PIK3CA  6201 PTEN  7106 
AKT2  10291 PIK3CB  7060 RPS6KB1  7916 
AKT3  9384 PIK3R1  12762 RPS6KB2  3996 
MTOR  16138 PIK3R2  8439   
Ras/MAPK ARAF  4444 MAP2K1  4702 NRAS 5554 
BRAF  5146 MAP2K2  4419 RAF1  5825 
HRAS  2228 MAPK1  7330   
KRAS 7873 MAPK3  4112   
Inflammatory response 
regulators  
NFKB1  8640 REL  4085 RELB  3879 
NFKB2  6538 RELA  4897   
Cytokines and their 
receptors CXCR1  3503 CXCR2  4718 IL8  2505 
 
2.3 Overview of sample preparation for sequencing 
Three major steps will be explained in the following text including: library preparation, target 
enrichment and template preparation. In the library preparation step the aim is to prepare a size 
selected DNA library from each patient and as well to barcode the DNA from different study 
participants with different barcode adaptors so that the libraries would be discriminated by the 
sequencing machine. The goal of the target enrichment step is to isolate only the sequences 
which are chosen (targeted) to be sequenced from the gDNA. Finally the prepared sample must 
be attached to an Ion Sphere Particle TM (ISP) and must be amplified in a way that a single 
molecule of DNA attaches to one ISP. The attached molecule will be then amplified. Figure 2.3.1 




Figure 2.3.1 Overview of sample preparation steps prior to sequencing. During these steps gDNA will be sheared and the fragments 
are then ligated to one barcode adaptor and one P1 adapter. Subsequently fragments with specific size (around 350 bp) are 
selected. After PCR amplification, the targeted regions are then isolated using specific biotinylated probes (shown in black). To 
evade and block the nonspecific hybridization between adaptor sequences and between genomic repeat regions, adaptor blockers 
and Human Cot1 DNA are added. Each DNA molecule is then attached to an Ion Sphere Particle (ISP) and an amplification 
procedure will be performed inside an oil microvesicle. The oil vesicle is then broken and amplified DNA attached to ISP is the 
result. Figure adopted from Ion Xpress™ Plus Fragment Library Preparation User Guide. 
 
2.4 DNA isolation and Library preparation 
In order to genotype the gDNA from our sample population, gDNA had to undergo several steps 
to finally be ready to be analyzed by the Ion Torrent TM sequencing machine. These steps include 
library preparation which produce gDNA libraries from each individual’s DNA sample which have 
a certain size and are bound to adaptor sequences. The Ion torrent sequencing application used 
in this study was a 200 bp read application which means that gDNA should be fragmented in a 
manner to produce fragments of about 200 bp length. The adaptor sequences were sequences 
of about 40 bp which are recognizable by the machine and contain signals for barcoding gDNA 
and identification of start point of sequencing. In the following gDNA fragmentation, selection of 




2.4.1 DNA isolation and genomic DNA fragmentation 
Genomic DNA was isolated from peripheral whole-blood samples utilizing QIAamp DNA Blood 
mini kit (Qiagen, Hilden, Germany).The aim of the following process was to prepare libraries from 
genomic DNA which are compatible with sequencing. Through this process genomic DNA was 
fragmented using an enzymatic reaction. For this reason0, Ion Xpress™ Plus Fragment Library 
Preparation kit was used. A mixture of restriction enzymes was used for this reason. However 
the composition of the enzyme mix was not revealed by the company; the result of the enzymatic 
reaction was blunt-ended DNA fragments. Depending on the duration of the enzymatic reaction, 
average size of the DNA fragments is different. The longer the reaction runs, the shorter the 
fragments will be. Figure 2.4.1 demonstrates the relation between time and fragment size 
analyzed with Bioanalyzer® instrument (not our data). 
 
Figure 2.4.1 Analysis of fragmented genomic DNA. Sample 1 was digested for a longer time than Sample 2. The peak of fragment 
size is shifted from 400 bp in Sample 2 to 150 bp in sample 1. Peaks at 35 and 10380 bp represent weight markers (Image from 
Ion Xpress™ Plus Fragment Library Preparation User Guide) 
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In each case, eight gDNA samples were prepared at once. Nuclease free water was added to 
obtain 500 ng/35 µl starting amount of the input gDNA. Afterwards Ion Shear 10X buffer – the 
buffer provided by the kit and is necessary for the enzymatic reaction – was added to a 1.5-mL Lo-
Bind tube containing 35 µl gDNA.  
Afterwards, the mixture was pre-incubated at 37oC in the heat block (Thermomixer 5436, 
Eppendorf, Hamburg, Germany) for minimum of 5 minutes. Then, 10 µl of the Ion Shear™ Plus 
Enzyme Mix II was added to the mixture and mixed thoroughly by pipetting up and down.  Next, 
the tubes were exactly 8 minutes on the heat block at 37°C. To stop the reaction, 5 μL of Ion 
Shear™ Stop Buffer was added and the reaction tube was stored on ice for 15 minutes. Finally, 
the reaction mixture was purified by Agencourt AMPure XP magnetic beads.  
 
These magnetic beads are covered with carboxyl molecules which in presence of polyethylene 
glycol (PEG) and salt will attach to negatively charged DNA. In order to do so, the DNA fragments 
were first bound to the magnetic beads, then using a magnetic rack (Dynal, Invitrogen) beads 
were immobilized. The immobilization facilitated the removal of supernatant. Afterwards, the 
beads were washed with freshly prepared 70% ethanol. Consequently, the DNA was dissolved in 
Low TE buffer. The beads were separated using the magnetic rack and were discarded. 
Fragmented DNA which is dissolved in Low TE could be stored at -20oC. 
 
2.4.2 Adaptor ligation 
After fragmentation, a pair of library adapters were ligated to each two sides of the fragmented 
DNA. Library adaptors were ~40 bp double-stranded DNA molecules which contained specific 
sequences. We have used two types of adaptors: Ion P1 AdaptorTM (which contains a sequence 
which used to attach to Ion Sphere Particles (ISPs)) and Barcoded adaptors (which contains 
"TCAG" key for library identification and a specific). Both adaptor types are blunt-ended on one 
side and have an overhanging single strand end on the other side. There are phosphorothioate 
bonds (shown with * in Table 2.4.1) which protect the nuclease activity. The overhanging single 
strand end ensures the directionality of the adaptor, meaning that the adaptor is only ligated to 
the DNA fragment from its blunt end, as the outcome of enzymatic DNA fragmentation is blunt 
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ended. Barcoded adaptors allow the sequencing of genomic DNA (e.g.) from different subjects or 
from different tissues in one sequencing run while maintaining the possibility to differentiate 
between the single subjects.  
Table 2.4.1 Adaptor sequences.  The IonXpress barcode set TM was used. TCAG (red) is the sequencing key which is a signal for 
the machine. The GAT sequence (green) is an indicator of target sequence initiation. The sequence in between is specific for each 
barcode. 
Name of the 
adaptor 








































































* represents a phosphorothioate bond 
The ligation reaction was performed as follows. Reagents displayed in Table 2.4.2 were added to 
a 0.2 ml PCR tube.  
Table 2.4.2 Reagents used in the ligation reaction of sheared DNA and adaptors. 
 
 
Afterwards, the tube was placed in a thermal cycler and the following program was performed 
not using heated lid option: 25°C for 15 minutes and then 72°C for 5 minutes. Finally the reaction 




The sequencing instrument, the Ion torrent Personalized Genome Machine TM (Ion PGM) has a 
certain read length for each sequencing application. We decided to use the 200 base-read 
application; therefore, we had to select a specific size of DNA fragments (which were already 
ligated to adapters). After ligation a size of 350 bp is needed for sequencing. To do so, each 
sample was run on a 2% agarose gel, and the 350 bp sized fragments were cut out from the gel. 
The gel piece was then subjected to DNA purification from the gel using Qiacube TM (Qiagen) 
robot and Qiaquick TM gel extraction kit (Qiagen). 
 
Reagent    Volume  (µl) 
Fragmented DNA  28 
10X Ligase Buffer  5 
Ion P1 Adapter  5  
Ion Xpress™ Barcode X  5  
dNTP Mix  1 
DNA Ligase  2  
Nick Repair Polymerase  4 
Total  50 
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2.4.4 Library amplification 
In addition to size selection, amplification is needed to reach the proper yield and proceed further 
to target enrichment. Amplification was performed using universal primers which anneal to the 
adaptors; subsequently, an amplification of whole gDNA is possible. To perform the 
amplification, 200 µl of Platinum® PCR SuperMix High Fidelity, 7.5 µl of Library Amplification 
Primer Mix and whole amount of purified size-selected library DNA were combined in a 1.5 ml 
Lo-bind tube and then were divided into two 0.2 ml PCR tubes. 
The reaction mixture was placed in a thermal cycler. And the program displayed in Table 2.4.3 was 
performed. 
Table 2.4.3 PCR program of library amplification after size selection. 
Stage  Step Temperature Time 
Holding Denaturation 95°C 5 min 
 Denaturation  95°C 15 sec 
14 cycles Annealing 58°C 15 sec 
 Extention 70°C 1 min 
Holding  4°C ∞ 
 
Subsequently the PCR products were purified using Agencourt AMPure XP magnetic beads. 
 
2.5 Analysis of library preparation efficacy 
After fragmentation, adaptors were ligated to the entire fragmented genomic DNA for each 
patient’s DNA sample. Subsequently, adaptor ligated gDNA was analyzed on 2% agarose gel. The 
350 bp region was then cut out. After purification of the DNA from the gel, amplification was 
performed. Figure 2.5.1 shows the documented agarose gel of representative samples selected 




Figure 2.5.1 Analysis of library preparation efficacy. A) Sheared and adaptor-ligated DNA, B) size selection performed by cutting 
out the gel piece of desired size, C) amplified size selected DNA templates. On the left and right side of the size markers two 
different samples are illustrated. 
2.6 Quantifying and pooling of amplified size selected libraries  
Considering the capacity of the sequencing chip, read length and the size of our target region, we 
decided to pool 9 genomic DNA libraries to be analyzed on a single sequencing chip. The Ion 
316TMsequencing chip has approximately 6 million wells, within each the polymerase reaction 
will take place. The size of our targeted region is 382,400 bases. Taking into account a 200 base-
read for each well in a perfect condition, each base could be 350 times read (average read depth 
or coverage of 350x) while pooling 9 samples.  
~350x coverage =
6000000 wells ∗  200 base read length 
9 libraries pooled ∗ 382400 size of the target region
 
Five hundred nanogram of a DNA pool is needed to start the next step. In order to normalize the 
libraries in such a way, that each individual’s library was equally represented in the pool, a 
quantitative real time PCR was performed. GeneRead DNAseq Library Quant Array (Qiagen) was 
used for this reason according the manufacturer’s instructions with minor modifications. The 
concentration is calculated in picomole/liter and in order to convert it to ng/µl an average size of 
330 bp and average mass of 660 ng/(nmol  bp) were assumed.   
In case there was enough library yield, a mass of 55 ng =
500 ng
9 𝑠𝑎𝑚𝑝𝑙𝑒𝑠
 from each library were pooled 
together. If the yield was not enough, equal masses of each library have been used for pooling 







Twenty one library pools were made, to sequence the 139 patients’ genomic DNA. Pool number 
7 was not successfully sequenced due to technical error. Pools’ gDNA mass and composition are 
shown in Table 2.6.1 Eleven pools were made with the recommended 500ng gDNA mass; 
however, other pools were prepared with less amount due to lack of required DNA 
concentration. In addition 11 pools were consisted of 9 samples, 1 pool had 10 samples and the 
other pools had 7 or 8 samples. If a sample would not enough over all coverage (50%), it would 

































1 500 2  500 3 500 4 500 5 500 6 500 8 238 
Barc. Samp. Barc. Samp. Barc. Samp. Barc. Samp. Barc. Samp. Barc. Samp. Barc. Samp. 
1 434 1 292 6 421 1 285 6 436 5 245 1 623 
2 297 2 430 7 263 2 302 7 215 9 645 2 219 
3 230 3 640 8 419 3 254 10 280 10 228 4 418 
4 213 4 433 9 278 4 432 11 634 11 231 5 221 
5 209 5 245 10 424 5 644 12 622 12 607 9 286 
6 646 13 287 11 626 8 632 13 256 13 222 11 259 
8 625 14 435 12 216 9 423 14 240 14 603 12 204 
9 627 15 225 13 276 15 416 16 608 15 229 14 260 





























9 207  10 130 11 169 12 500 13 500 14 500 15 355 
Barc. Samp. Barc. Samp. Barc. Samp. Barc. Samp. Barc. Samp. Barc. Samp. Barc. Samp. 
3 635 2 264 1 275 1 247 4 212 4 284 1 643 
6 211 3 609 2 207 2 638 4 413 8 601 3 602 
7 234 5 205 3 417 3 629 5 246 9 283 5 273 
8 620 6 255 4 268 4 619 6 201 10 220 7 261 
10 235 7 252 5 642 9 237 7 621 11 257 11 412 
13 270 8 293 6 630 10 611 8 271 13 251 12 233 
16 238 10 624 9 242 11 612 11 604 14 223 13 275 
  12 203 13 244 12 241 13 279 15 227 14 609 
  16 628 14 605 15 206 14 281 16 411 16 236 


























16 147 17 144 18 500 19 500 20 162 21 94   
Barc. Samp. Barc. Samp. Barc. Samp. Barc. Samp. Barc. Samp. Barc. Samp.   
1 249 7 616 2 214 1 210 5 270 5 622   
2 633 8 293 9 627 3 249 9 202 6 626   
6 255 9 267 10 282 4 252 10 607 7 634   
7 260 10 641 12 617 8 271 11 415 8 635   
8 210 12 614 13 610 9 603 12 609 13 637   
9 414 13 275 14 240 11 608 14 639 15 645   
10 637 14 218 15 624 12 241 16 625 16 648   
11 243 15 613           
12 288 16 243           
Pool numbers and the corresponding gDNA concentration is displayed in the above table. The composition of each 
pool (DNA sample numbers) and the corresponding barcode number are also displayed  
2.7 Target enrichment 
Having the gDNA libraries prepared, in the next step we needed to select the target regions and 
enrich them in our libraries. As only specific target genes were selected, DNA probes were 
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designed to capture only the specific targets. The probes were single strand DNA biotinylated 
oligonucleotides. The probe-hybridized target regions of our libraries were isolated using the 
biotinylated probes using streptatvidin-magnet beads. Target enrichment by hybridization is 
actually consisted of two hybridizations: A first hybridization of the library, then a PCR 
amplification of the enriched sequences and then a second hybridization which ensures the 
isolation of target regions from the other genomic regions and decreasing the off-target reads. 
 
2.7.1 First hybridization  
2.7.1.1 Adaptor and repeat sequence blocking 
Before the first hybridization (target capture), adaptor blockers and Human Cot-1 DNA were 
added to the pooled DNA libraries. Human Cot-1 DNA ® (the name Cot or C0T stems from the 
fraction of concentration (or C) of single stranded DNA which remain single stranded after a 
certain time (or T)) is a placental DNA that is mainly 50 to 300 bp in size and rich in repetitive DNA 
sequences. These sequences tend to hybridize to each other; as a consequence, probe 
hybridization to target sequence will be problematic. Human Cot-1 DNA ® along with adaptor 
blockers were used to prevent non-specific hybridization.  Mechanism of action of adaptor 
blockers and Human Cot-1 DNA ® is shown in Figure 2.7.1. 
Practically, 5 µl each of Ion TargetSeq™ Blocker BC 1–16, Ion TargetSeq™ Blocker P1 and Human 
Cot-1 DNA where added to the pooled libraries in a Lo-bind tube. In addition, a hole was made in 
cap of the tube using a sterile 20 gauge needle. Afterwards, using a vacuum-concentrator (Savant 
Instruments, Farmingdale, NY) set to 60 oC the mixture was dried for 30 minutes (untill it was 




Figure 2.7.1 Mechanism of action of adaptor blockers and Human Cot-1 DNA. Common sequences in adaptors cause attachment 
of adaptor ligated DNA to attach together and hinder the hybridization process. In addition this nonspecific hybridization may 
also occur in between repeat sequences of the genome. Figure adopted from Targetseq TM Custom Enrichment User Guide 
 
 
2.7.1.2 First Hybridization procedure 
Target enrichment is performed by biotinylated probes which contain complimentary sequences 
to the target regions. The used TargetseqTM Custom Enrichment kit contains a custom probe pool, 
in which – according to manufacturers – every base in target region is at least covered by 4 
different probes. The biotinylation permits the isolation of these probes by streptavidin beads 
(Dynabeads M-270 Streptavidin, Life Technologies).  
To perform this step, 7.5 µl of the TargetSeq™ Hybridization Solution A (2X) and 3 µl of the 
TargetSeq™ Hybridization Enhancer B were added to the dried tube. The tube was then put in a 
95oC heatblock for 10 minutes to denature the double-stranded DNA. Next, 2.25 µl of custom 
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probe pool and 2.25 µl nuclease-free water were added to the tube. Afterwards, the tube was 
placed in a thermal cycler at 47oC for more than 12 hour while using heated lid option. 
2.7.1.3 Washing and recovery of probe hybridized DNA 
The entire amount of PCR product was transferred to the tube containing streptavidin beads 
(Dynabeads M-270 Streptavidin, Life Technologies). After thoroughly mixing the beads with 
hybridization mixture, the tube was placed back to the thermal cycler for 45 minutes. This 
allowed the biotinylated probes to bind to the streptavidin beads. Afterwards, several washing 
steps were performed using 4 different washing solutions namely “stringent wash solution”, and 
then wash solutions A, B and C. After washing, the beads were resuspended in 40 µl of LTE buffer. 
 
2.7.1.4 Amplification and purification of the first capture reaction 
To amplify the captured DNA a PCR reaction was performed using universal primers. The 
captured DNA, which was still attached to the streptavidin beads, was used as the template. 200 
µl of Platinum® PCR SuperMix High Fidelity, 10 µl of Library Amplification Primer Mix and 40 µl of 
TargetSeq capture beads with DNA were combined and then the PCR reaction described in 
Table 2.7.1 was executed. 
Table 2.7.1 Amplification of the first capture reaction. 
Stage  Step Temperature Time 
Holding Denaturation 95°C 5 min 
 Denaturation 95°C 15 sec 
5 cycles Annealing 58°C 15 sec 
 Extension 70°C 1 min 
Holding  4°C ∞ 
 
Contents of the PCR tube were then added to a Lo-bind tube and the tube was place on a 
magnetic rack. The supernatant contained our amplified target region and the beads were 





2.7.2 Second hybridization 
Second hybridization procedure was performed almost the same as first hybridization process 
with steps as described in 2.5.2.1 to 2.5.2.4 and the exception of only difference of 14 cycles 
amplification at the last step. 
 
2.8 Template preparation 
Previously prepared size selected adaptor ligated libraries enriched for the target region were 
now available for the next steps. These libraries should undergo a template preparation step to 
be ready for loading on the sequencing chip and starting the sequencing. These steps include 
emulsion PCR in which a template is attached to plastic microscopic spheres (Ion Sphere Particles, 
ISP) and is then amplified. Finally the spheres which were connected to the amplified template 
will be enriched and prepared for sequencing. 
 
2.8.1 Enriched pooled library quantification  
A quantitative real time PCR was performed to quantify the enriched pooled library. GeneRead 
DNAseq Library Quant Array (Qiagen) was used for this reason according the manufacturer’s 
instructions with minor modifications. The concentration was calculated in picomolar and the 
pools were diluted to reach a 10pM concentration.  The quantification step is necessary for 
performing emulsion PCR, as the ratio of DNA molecules to number of ISP has a vital role in 
quality of template.  
 
2.8.2 Emulsion PCR  
The Ion OneTouchTM System was used to prepare the template for sequencing. Adaptor ligated 
DNA and ISPs are introduced to Ion OneTouchTM machine. Emulsion PCR (Figure 2.8.1) is the main 
function of this machine(Dressman et al. 2003). In this process a PCR reaction will take place 
inside a water-in-oil microemulsion, resulting in amplification of the one DNA molecule attached 
to a single ISP (Ion Sphere Particle).This PCR reaction is performed using biotinylated primers 
with the purpose of isolation of the harvest by streptavidin magnet beads. As a result, millions of 
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copies of a certain DNA piece will be attached to one ISP. Then the emulsion is broken and as a 
result ISP bound DNA is prepared for sequencing.  
This is the optimal scenario that could happen; however, there might also be copies of different 
DNA pieces attached to one ISP that makes the sequencing for this ISP impossible (Figure 2.8.2).  
This scenario is called polyclonality. In order to avoid this problem, the ratio of ISP to DNA 
molecules must be as close as possible to 1:1.  
 
Figure 2.8.1 Emulsion PCR. In this process one DNA template will be amplified in one microemulsion oil sphere attached to an ion 
sphere particle (ISP). By quantification of DNA templates a 1 to 1 ratio of template to ISP will be facilitated. PCR primers and DNA 
polymerase are also added PCR amplification to this reaction. 
 
For this reason 20 µl of enriched library pool was added to 500 µl of Ion OneTouch TM 2x reagent 
Mix, 280 µl nuclease-free water, 100 µl Ion OneTouch TM Enzyme Mix and 100 µl Ion OneTouch 
TM 200 Ion Sphere TM Particles (parts of Ion OneTouch TM 200 Template Kit v2 DL). After mixing 
thoroughly the reaction mixture was loaded on Ion OneTouch TM Reaction Filter Assembly. 
Afterwards, 1500 µl of OneTouch TM reaction oil was the added to the filter. Then the filter was 
firmly inserted into OneTouch machine top stage. Finally the reaction was started. The duration 






Figure 2.8.2 Emulsion PCR difficulties. Several erroneous scenarios might happen while performing emulsion PCR. An ISP without 
any DNA template or a vesicle with DNA templates but with no ISP result in an invalid outcome. Also several different templates 
may be amplified while being attached to one ISP which results in polyclonality (cannot be used for sequencing). 
2.8.3 ISP Enrichment 
ISP enrichment is a process, in which the ISPs that are not attached to DNA are isolated and 
discarded. To do so, streptavidin magnetic beads were used (Dynabeads® MyOne™ C1, Life 
Technologies). Magnetic beads attach to the amplified DNA molecules via the biotinylated site. 
The beads can be isolated by a magnetic field; consequently, ISPs which does not contain DNA, 
stay in supernatant and can be discarded. Afterwards, the hydrogen bounds between two DNA 
strands were broken using a highly alkaline solution (melt-off solution). This time using a 
magnetic field the beads can be separated from ISPs and can be discarded (Figure 2.8.3). 
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In order to perform this procedure, we have used Ion OneTouchTM ES instrument. First of all, the 
melt off solution was prepared as following: 10 µl 20% TWEEN was added to 125 µl 0.1M NaOH 
solution and 865 µl nuclease-free water. Ion OneTouchTM ES instrument 8 well strip was loaded 
according to Table 2.8.1 . The strip was then placed on Ion OneTouchTM ES instrument. An 
enrichment procedure lasts about 40 minutes. After completion of the procedure the ISPs were 
washed twice with 100 µl of Ion OneTouch™ Wash Solution. Finally the template was ready for 
sequencing. 
Figure 2.8.3 ISP enrichment. Through this process only ISPs which are bound to DNA templates are selected. 
 
Table 2.8.1 Onetouch ES 8 well strip’s wells contents 
Well number Reagent to dispense in well 
1 Entire template-positive ISP sample (100 μL) 
2 130 μL of Dynabeads® MyOne™ Streptavidin C1 
3 300 μL of Ion OneTouch™ Wash Solution 
4 300 μL of Ion OneTouch™ Wash Solution 
5 300 μL of Ion OneTouch™ Wash Solution 
6 Empty 







2.9 Massively Parallel Sequencing  
In this study, we have used Ion torrent PGM which is a semi-conductor based sequencing device. 
The basis of this method is the detection of pH changes following the release of proton after each 
base is added to the DNA structure by the polymerase enzyme. The prepared templates should 
be loaded on a chip which contains several wells. Each sequencing reaction happens in a well 
which is smallest unit of sequencing in this technique. Each well has the capacity of one ISP. 
Depending on the type of the chip the number of wells that they contain varies. Chips Ion 314, 
316 and 318 contain 1.2, 6.1 and 11 million wells respectively. Structure of a well is shown in 
Figure 2.9.1. During sequencing dNTPs are added one after another and in case they are 




2.9.1 Addition of sequencing primer and sequencing polymerase  
Ion PGM 200 Sequencing kit and Ion 316 chip were used in our study. Five microliters of Control 
ISPs were added to the enriched template and then 100 µl of Annealing buffer was added to the 
solution. After centrifuging only 15 µl of reaction mix was kept and the rest was discarded. Twelve 
microliters of sequencing primers were added to remaining reaction mix and was placed in a 
A B 
Figure 2.9.1 Structure of an Ion chip and base calling. Figure A shows the cross-section of one sequencing well of the ion chip. 
Hydrogens released during the sequencing reaction are marked and will be detected by the microarray as indicated. Figure B 
illustrates the base-calling. The intensity of the signal could indicate the number of nucleotides when there is more than one of a 
certain nucleotide in a row. Taken from Rothberg et al. Nature 475, 348-352 (2011) doi:10.1038/nature10242 
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thermal cycler for annealing process. A program with 2 minutes in 95oC and then 2 minutes at 
37oC was performed. After thermal cycling, 3 µl polymerase enzyme was added to the tube to 
finally reach the volume of 30 µl. The reaction mixture was incubated in room temperature for 5 
minutes.  
 
2.9.2 Loading the sequencing chip 
Ion 316 chips (Figure 2.9.2) were used in this study. The chip contains a loading port, from where 
the template should be loaded. Before loading the templates, 100 µl isopropanol was loaded on 
the chip. Next, the excess liquid should be removed from the other port. This step should be 
repeated 2 times using 100 µl annealing buffer. Subsequently, 30 µl template was loaded on the 
chip. The pipette tip was fixed firmly on loading port and then the pipette was slowly dialed down 
to load the liquid on the chip.  The chip was then centrifuged to seed the ISPs inside the wells. 
Finally, the chip was then placed in PGM. 
Figure 2.9.2 Ion 316 chip (Image from Ion PGM™ 200 Sequencing Kit User Guide) 
 
2.9.3 Sequencing 
The Ion torrent sequencing machine or PGM is connected to a computer server. The server is 
responsible for analysis of signals provided by PGM. The software controlling this sever is called 
Torrent suite. We have used Torrent suite version 3.6.2 for our analysis.  
Before running the sequencer, a run should have been planned using Torrent suite software. Run 
planning requires the info regarding: the kits used for preparation of sequencing template, the 
barcode set, respective names of each sample for each barcode, sequencing application and 
targeted regions.  
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For each run, the predefined plan was selected from the PGM console and matched with the 
loaded chip. Each run took about 3 hours. After each run, the torrent server starts to analyze the 
generated sequences and to align them to the selected reference sequence. Torrent suite also 
includes plug-ins such as Torrent Variant Caller (TVC) and coverage analysis. 
Coverage analysis surveys the coverage of selected target region. The file containing coordinates 
of target regions was uploaded in Torrent suite prior to using the PGM for the first time. TVC is 
the plug-in which identifies the variations found in gene sequences compared to the reference 
genome.  
2.10 Variant calling 
To discover the single nucleotide variants (SNVs) two softwares were used: DNAstar and Torrent 
Variant Caller plug-in of Torrent suite which are described in the following text. 
2.10.1 DNAstar software 
DNAstar (version 11.1) is a commercial software package, in which we have used Seqman NGen, 
Seqman Pro and Arraystar. Seqman NGen aligns the sequences to the reference genome, which 
in this case was human genome version 19. Seqman Pro was used to visualize the sequences. 
Arraystar was used to compare genotypes of all variants in all patients along with the coverage 
at this position in a single table. 
Using Seqman Ngen software the variants were called. The parameters used were as following 
Mer size(or K-mer size which indicates the number of nucleotides which are considered as a unit 
in alignments) and minimum matching percentage were set to automatic, genome ploidy was set 
to Diploid, in the SNP tab of advanced options “calculate SNPs” was checked, minimum SNP 
percentage was set to 0, SNP confidence threshold was adjusted to 0, minimum SNP-count was 




2.10.2 Torrent Variant Caller 
Torrent Variant Caller identifies single-nucleotide polymorphisms (SNPs), multinucleotide 
polymorphisms (MNPs), insertions, and deletions in performed sequencing analysis. TVC does 
this action in two following steps. 
Step 1 is to survey the aligned sequences and subsequently, find candidate regions which have 
evidences of presence of a variant in the examined region. These regions are then marked as 
probably containing a variant. Candidate regions must pass a minimal set of requirements (such 
as read quality, minimum coverage, etc.) (Garrison E 2012).  
Step 2 is to additionally assess the candidate variant identified in step 1 to assign the confidence 
rate of each variant and also to assign the genotype. Candidate positions are then evaluated by 
a statistical model offered from GATK. GATK is a software package developed at the Broad 
Institute to analyze next-generation resequencing data. Finally, to decide if the assumptions of 
the model are not in agreement with the data, variants are filtered by several criteria.  
All of these actions are controlled by predefined parameters provided for the software. It is 
possible to use pre-configured parameter settings in accordance with the estimated variant 
frequency in the sample (Germline or Somatic) and the desired stringency level of the calls. On 
the other hand, Torrent Variant Caller offers users to define the parameters, depending on their 
population and aims. 
The Torrent Variant Caller has an output file for each individual; in which only the variations are 
displayed. Using these output files by collecting the variations found a hotspot file containing all 
variants was made and uploaded to Torrent suite. This file contains a list of chromosomal 
positions, along with the reference and alternative allele belonging to that position. This file (the 
hotspot file) obliges the TVC to analyze and report all listed positions in the hotspot file, even if 
the called allele is not a variant. Consequently, it was determined whether the lack of the call is 





Figure 2.10.1 Screen-shot of a Torrent variant caller output. In the top section information regarding the sequencing run name, 
application type, barcode name, the parameters used for variant calling along with a summary of the variations found are 
displayed. A bar chart of variations found categorized by chromosome is shown on the right side. Finally the variants are shown 
at the bottom. Data regarding variants’ chromosomal position, alleles and the quality of sequencing at the position are 
demonstrated. 
 
Figure 2.10.1 shows a representative sample’s Torrent Variant Caller output view. The plug-in 
output files, can be loaded into Broad Institute's Integrative Genomics Viewer for further 
visualization or analysis (Thorvaldsdóttir et al. 2013). Upon clicking, the link opens and displays 
all reads covering the chromosomal position. Figure 2.10.2 shows a representative heterozygote 




Figure 2.10.2 Integrative Genome Viewer (IGV) interface. Overview of IGV interface for showing a C to T variation. Gray bars 
represent the reads. Each horizontal grey bar indicates one read. All reads are aligned by the software and the variants are marked. 
Here only a selected number of the reads at that position are illustrated. 
 
Two pre-configured settings for germline SNPs were applied to the analysis. These configurations 
were High stringency and Low stringency. Table 2.10.1 displays the settings used in analysis using 
Torrent Variant Caller. After surveying the results of these analyses, a custom setting was made 




Table 2.10.1 Torrent Variant Caller parameter configurations. The steps after which we decided to use custom parameters are 
stated in paragraph 3.4.3. 





Parameter      
data_quality_stringency 8.5 6.5 8.5 
hp_max_length 8 8 8 
filter_unusual_predictions 0.25 0.3 0.25 
filter_insertion_predictions 0.2 0.2 0.2 
filter_deletion_predictions 0.2 0.2 0.2 
snp_min_cov_each_strand 3 0 3 
snp_min_variant_score 10 10 10 
snp_min_allele_freq 0.15 0.1 0.15 
snp_min_coverage 20 6 10 
snp_strand_bias 0.95 0.95 0.95 
snp_beta_bias 8 30 8 
indel_min_cov_each_strand 3 5 3 
indel_min_variant_score 10 10 10 
indel_min_allele_freq 0.15 0.1 0.15 
indel_min_coverage 20 15 20 
indel_strand_bias 0.85 0.85 0.85 
indel_beta_bias 8 8 8 
hotspot_min_cov_each_strand 3 3 3 
hotspot_min_variant_score 10 10 10 
hotspot_min_allele_freq 0.15 0.1 0.15 
hotspot_min_coverage 20 6 10 
hotspot_strand_bias 0.95 0.95 0.95 
hotspot_beta_bias 8 30 8 
downsample_to_coverage 400 400 400 
outlier_probability 0.01 0.01 0.01 
prediction_precision 1 1 1 
heavy_tailed 3 3 3 
kmer_len 19 19 19 
min_var_count 5 5 5 
short_suffix_match 5 5 5 
min_indel_size 4 4 4 
max_hp_length 8 8 8 
min_var_freq 0.15 0.15 0.15 
relative_strand_bias 0.8 0.8 0.8 
Parameters in blue color which control the minimum coverage acceptable are modified to prepare the custom parameters from 




2.11 Statistical analysis and functional prediction of nonsynonymous variants 
Single marker association analysis of SNPs and skin rash was performed in two phases. In the first 
and second phases we have dichotomized patients regarding skin rash to respectively grade 0 
compared to grade 1 or higher, and grade 0-1 compared to grade 2 or higher. Single marker 
analysis was performed with Plink software (version v1.07) using Fisher’s exact test for genotypic 
along with allelic models(Purcell et al. 2007). Fisher-Freeman-Halton 2x3 exact test, an extension 
for Fisher’s test which can be used for 2x3 tables, has been used for 2x3 tables. In genotypic 
model each individuals’ genotypes (considering r as reference and A as alternative alleles, rr, rA 
and AA) are as units which are hypothesized to affect the dependent variable. On the other hand, 
in the allelic test number of alleles (number of r or A alleles) of each subject’s genotype are 
considered to correspond to the presence of dependent variable (in this text skin rash) 
(Figure 2.11.1). Correction for multiple testing considering 1437 variants resulted in P value of 
0.000035 as the level of significance required for single marker testing. 
 
Figure 2.11.1 Explanation of genotypic and allelic models. The crosstabulation regarding each of these models is displayed. r : 
reference allele; A: Alternative allele. 
The linkage data was analyzed using haploview software (v 4.2) (Barrett et al. 2005). Association 
plots were created using integrative genomics viewer software (Thorvaldsdóttir et al. 2013). 
Prediction of SNPs’ functionality was performed using SIFT (Sort Intolerant from Tolerant amino 
acid substitutions, v1.0.3), Provean (Protein Variation Effect Analyzer, v 1.1.3) and Polyphen2 
(Polymorphism Phenotyping v2 v2.2.2) tools (Adzhubei et al. 2010, Choi et al. 2012, Kumar et al. 
2009). These tools use algorithms which are trained by known in vitro data for changed 
functionality. As an example input and output data of Polyphene2 tools is stated in the following. 
As an input chr1:11190646 C/G was entered and the output can be found in Table 2.11.1.  
Genotypic test Allelic test
dependent variable dependent variable 
absent present absent present
No. of rr a b No. of r a b
No. of rA c d No. of A c d
No. of AA e f
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Table 2.11.1 An example output data of Polyphen2 prediction tool. 
Chrom. Position Gene nt1 nt2 pos aa1 aa2 Based on pph2 prediction 




Gene-based and pathway-based analysis was performed with plink/seq (version 0.08 
http://atgu.mgh.harvard.edu/plinkseq/index.shtml) using gene burden test, C-alpha test, 
Frequency-weighted test, Variable threshold test, UNIQ and summary statistics. Rare SNPs that 
where predicted to be damaging by any of three softwares (SIFT, Provean or Polyphen2) were 
enrolled in this analysis. Rare SNPs were defined as less than 13 minor allele count which was 
calculated considering 126 patients and MAF of less than 5%. Minor allele count was used instead 







One hundred and twenty six patients 
receiving EGFR inhibition therapy from 
September 2008 to December 2010 were 
enrolled in this multicenter study. 
Patients’ demographic data are presented 
in Table 3.1.1. Median and mean age were 
68 and 66.6 years (43-86 years). The 
majority of patients were receiving 
erlotinib (73 %) while cetuximab was the 
second frequent drug (22.2 %). Sixty one 
percent of patients had bronchial cancer; 
in addition, 32.5%, 4%, 0.8% and 0.8% 
were affected with pancreatic, colon, 
HNSCC and upper GI cancers respectively.  
Occurrence and severity of skin rash was 
surveyed in this study. Skin rash occurred 
in 80.2 % of the patients taking EGFRIs. 
The majority of patients with skin toxicity 
had grade 1 skin rash (38.1%) and a close 
number had grade 2 rash. Only 6 patients 
(4.8%) were affected with grade 3 rash. 
Grade 4 or generalized rash was not 




Table 3.1.1 Patient characteristics 
Characteristic   N % 
Age    
 Median (range) 68 (43-86)   
Sex    
 Male 83 65.9 
 Female 43 34.1 
EGFRI    
 Erlotinib 92 73.0 
 Gefitinib 4 3.2 
 Cetuximab 28 22.2 
 Panitumumab 2 1.6 
Disease    
 Bronchial Cancer 77 61.1 
 Colon Cancer 5 4.0 
 Head and neck SCC 1 0.8 
 Pancreatic Cancer 41 32.5 
 Upper gastrointestinal 
Cancer 
1 0.8 
Smoking    
 Never 38 30.2 
 Former 63 50.0 
 Present 16 12.7 
 NA 9 7.1 
Clinical stage    
 IIIa 2 1.6 
 IIIb 16 12.7 
 IV 102 81.0 
 NA 5 4.0 
Skin rash grade    
 0 25 19.8 
 1 48 38.1 
 2 47 37.3 
 3 6 4.8 
Diarrhea grade    
 0 81 64.3 
 1 25 19.8 
 2 15 11.9 
 3 4 3.2 
 4 1 0.8 
As shown in the table, patients received either one of the small 
molecule tyrosin kinase inhibitors or monoclonal antibodies. 
Clinical staging was according to Classification of Malignant 
Tumors (TNM) and grading of the adverse effects was done 




Since we have chosen skin rash along with diarrhea and survival as parameters for the 
pharmacogenomics analysis, it may be interesting to know how much these parameters are 
correlated to each other. If similar processes are underlying, there might be correlations in 
between these parameters. As a simple approach to this question we illustrate the correlation 
between the parameters in spine plots and scatterplots. 
In Figure 3.1.1 the correlation between diarrhea and skin rash is illustrated. A Spearman’s rank 
correlation coefficient of 0.14 was calculated and there was no significant correlation between 
skin rash and diarrhea (P value of 0.10).  
 
 
Figure 3.1.1 Spine plot of correlation of skin rash and diarrhea in study population. A correlation 
was not observed. The size and the color intensity of squares represent the number of patients. 
Diarrhea did not occur frequently (mainly grade 0). 
61 
 
The correlation between skin rash and overall survival is similarly illustrated in Figure 3.1.2. In 
this correlation only those patients could be considered who passed away in the observation 
period. A more complete correlation using Kaplan-Meier-Plots with the present sample has 
already been published by (Paul et al. 2014) and is in addition illustrated here. The same survey 
Figure 3.1.2 Correlation between skin rash and survival in patients who passed away during 
the study period. A trend for a better survival was observed in patients with higher levels 
of skin rash. Several patients in skin rash grade 3 group were alive at the last day of follow 
up and therefore this group is small in this survey. Survival time is calculated and displayed 
in days. 
Figure 3.1.3 Correlation between diarrhea and survival in patients who passed away during 
the study period. A correlation between survival and overall survival was not observed. 
Several patients in skin rash grade 3 group were alive at the last day of follow up and 
therefore this group is small in this survey. Survival time is calculated and displayed in days. 
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was performed for assessing the correlation between diarrhea and overall survival. No 
correlation was observed. 
Next to these questions, an important question is about the confounding factors which would 
have to be considered in the genotype-phenotype correlation analysis. Therefore, we analyzed 
whether skin rash, diarrhea and survival (the latter in the subgroup with known time of death 
only) were correlated with gender (Figure 3.1.4) or age (Figure 3.1.5). No correlations were found 




Figure 3.1.4 Correlation between gender and skin rash, diarrhea and survival. Survival was assessed only in 














Figure 3.1.5 Correlation between age and skin rash, diarrhea and survival. Survival was assessed only in patients who 
passed away during the study period. There was no correlations between age and phenotypes studied. 
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3.2 Target enrichment 
The file including the target regions’ chromosomal positions has been uploaded to the 
sequencing machine’s server computer (see 2.1 in methods). Subsequently, identification of 
reads which were aligned to the target region or unwantedly to other genomic regions was 
facilitated. Average percentage of on-target reads (reads which were aligned to target region) 
was 93% (80%-96%, the lowest percentage through the highest in a sequencing analysis). 
Moreover, 94% (65%-99%) of target bases were at least one time covered. On average, 85% (52%- 
98%) of the target region was at least 20 times covered. Figure 3.2.1 displays the visual coverage 
of EGFR, NFKB2 and MAPK3 in a representative sample. 
  
Figure 3.2.1 Target enrichment efficacy and coverage analysis. In all these examples a high coverage was achieved. A) Coverage 
of EGFR gene. The whole EGFR gene was targeted which is approximately 200 kb long. The variations are shown in form of 
colored lines. As the region sequenced in EGFR gene was larger than other genes, the frequency of variations was higher. B) and 
C) NFKB2 and MAPK3 genes (respectively) in a representative sample. Red bars track represent our target region. Coverage is 
shown in a logarithmic scale. Figures are demonstrated using integrative genome viewer. The blue line displays the genomic 
region in each figure. 
C) 
 





















3.3 Template preparation, loading the sequencing chip and massively parallel 
sequencing 
After sequencing the 20 pools (180 libraries including several which had to be repeated), an 
average percentage of 73% of the wells in each chip were loaded and the range between all chips 
was 36% to 89%. Mean polyclonality was calculated to be 27% (16%-45%). On average, 443 
megabases were sequenced in each sequencing run (ranging from 147 to 604 megabases). 
Overall 8859 megabases (8.859.000.000 bp) were aligned to the human genome version 19 
(hg19) by the Torrent suite TM software.  
3.4 Variant detection 
3.4.1 DNAstar software and Torrent Variant Caller variants 
Using DNAstar software parameters, 3757 variants were found. On the other hand, using the 
Torrent Variant Caller with software settings for germline high stringency, 1712 variants were 
found. Minimum coverage required in this setting was 20, and variants with less coverage have 
been excluded. The number of variants found with the Torrent Variant Caller software utilizing 
germline low stringency settings was 2276. Minimum coverage required in this set of parameters 
was 6x.  
 
3.4.2 Comparison of variants found using high stringency, low stringency and DNAstar software 
and a description of occurred problems 
Table 3.4.1 displays the numbers of common variants between different variant calling 
procedures. A table of all 1655 common variant calls among all three analyses for every position 
was made. Variant calls of each procedure were in columns beside each other. Consequently, a 




Table 3.4.1 Number of common variants between two Torrent Variant Caller settings and DNAstar software.  
 DNAstar  Torrent variant caller 
High stringency Low stringency 
DNAstar  3757  1655  1757  
High stringency  1655  1712  1712  
Low stringency 1757 1712  2276  
Quantities in the intersection of columns and rows indicate the number of common variants found among the settings 
represented by the selected column and row  
At this point considering 1655 positions in 139 samples, 230045 base calls were present for 
analysis. Approximately 27% of calls were discrepant between DNAstar and either one of the 
Torrent Variant Caller settings. On the other hand, the percentage of discrepant calls was only 
2.6% in between two Torrent Variant Caller settings: high and low stringency. Observation and 
analysis of the discrepancies between DNAstar and two other settings revealed shortcomings for 
DNAstar such as wrong calls (including several examples of calling a certain allele in absence of 
even one read showing the called allele). Therefore, we excluded the DNAstar analysis from 
further analysis. After comparison, 5849 discrepancies were found between high and low 
stringency settings.  
Figure 3.4.1 Common variants between two Torrent Variant Caller settings and DNAstar software. For a better understanding a 
Venn diagram is depicted. The blue circle represents the DNAstar software variants. The green and the red circles represent 



































































































Several types of problems appeared when the discrepant calls were investigated. We decided to 
analyze the discrepancies between two settings of Torrent Variant Caller settings starting from 
the subject number 201 continuing to get a better understanding of discrepancies’ origin. After 
we were observing repetitive problems we stopped the checking process. As a sample, 13.7% 
(798) of discrepancies were surveyed manually one after another. The integrative genome viewer 
view for each of these discrepancies was investigated. In 39.5% of the cases the variant call from 
high stringency setting was more confidently acceptable. These were the cases which confidence 
of call was low. In 16.7% of cases the coverage was between 10 and 20 (in the high stringency 
setting minimum coverage acceptable was 20 and in low stringency minimum was 10). Therefore, 
high stringency setting had no call and on the other hand the low stringency had the call which 
was without apparent error. In remaining 43.8%, making an acceptable call was not possible 
considering the quality and depth of coverage at those points (Table 3.4.2). In these instances, 
high stringency setting had a “no call” result and we decided to consider it the right call in order 





Table 3.4.2 Analysis of discrepancies between Torrent Variant Caller settings high and low stringency. 




Low quality of the reads 
according to the quality score  
 
316 (39.5%) Accepting high stringency 
Between 10 to 20x coverage 134 (16.7%) Decided to change the minimum 
coverage parameter in custom setting 
Imbalance between positive 
and negative reads in 
heterozygote positions 
371 (43.8%) High stringency calls were accepted to 
avoid false positive 
 
The following is the description of typical problems encountered. A table of comparison for each 
position’s call by each procedure along with an integrative genomic viewer outlook of the 




3.4.2.1 Problem one: Homopolymers 
One of the shortcomings of Ion torrent sequencing is the homopolymer problem. This problem 
occurs when there is a repeat of the same base. Due to the method of base calling in Ion torrent 
sequencing, distinction between numbers of bases in homopolymeric repeat regions is less 
confidently possible. In the following example the reference base is G and the alternate one is T.  
Total read count is 92 times and 14% of the reads show G and 84% show a T in this position. There 
is a five-time G repetition in the region; therefore, the number of G bases was not well detected 
due to the mentioned homopolymer problem. Consequently, the T is occasionally placed in the 
further position. DNAstar software and Torrent Variant Caller setting high stringency have a T/T 
call; however, the low stringency has the wrong G/T call. In this case variant caller is unable to 
call the variant correctly. High stringency has more stringent parameters therefore it has a better 
discrimination in homopolymer cases. 
   
Patient 238  DNAstar  High stringency  Low stringency  














Figure 3.4.2 The integrative genomics view of a problem occurred due to a homopolymer region. Wrong G insertions are 
detected by the variant caller due to this problem. 
70 
 
Number of “no call” results was significantly higher in five and four homopolymer regions in 
comparison to regions with less or no homopolymers (P value < 0.001, independent sample T 
test). Quality score is a confidence level in which the variant calling was performed. It is 
determined by the torrent suite and the sequencing machine. This score is equal to -10 log10 
(error rate), meaning that in case 1 out of 10 calls are wrong – thus the confidence is 90% – 
therefore the quality score is equal to 10 (Q10). In case of homo four-mers mean number of no 
calls and average quality are 37.96 and 59.87 respectively in comparison to 24.63 and 60.10 in 
regions with less than four homo-mers (numbers and figures are based on custom parameter 
settings’ calls which will be explained later). Figure 3.4.3 shows the association between existence 
of regions of five-mer and four-mers and higher number of “no call” results and the lower average 
quality of the variant calling. However high stringency setting had a right variant calling in the 
represented problem; we have excluded regions with homopolymers of more than 3 base from 
our study. 
Figure 3.4.3 Homopolymer as reason for low quality and missing calls. This figure displays error bars of association between 
homopolymer regions and quality of calls along as well as with non-missing calls. As it is displayed in this figure, in case of homo 
3-mers number of no calls and average quality are quite similar. But in case of homo 4-mers or more, quality was significantly 




3.4.2.2 Problem two: Low coverage 
In the example shown below, depth of coverage is 12x (more than 10 which is the considered 
limit for an acceptable coverage) (Wheeler et al. 2008). The reference allele was C in this position. 
All 12 reads were T and the quality of the reads was adequate (judged by the color of reads in 
integrative genomics viewer). In this case, high stringency setting had no call and other 
configurations have a T/T call. The reason of not having a call in high stringency setting is the 
minimum 20x required coverage was set in the parameters. To overcome this problem, minimum 
coverage was set to 10 in the custom parameter setting which was used later for variant calling. 
 
  
Patient 203  DNAstar  High stringency  Low stringency  













Figure 3.4.4 The integrative genomics view of a problem occurred due to a low coverage. Twelve reads were achieved in this 
instance, which are enough for variant calling. However the high stringency setting of Torrent Variant Caller do not achieve a 
result due to its parameter setting and reports no call. 
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3.4.3 Custom parameters as a solution 
Considering the mentioned problems, we have changed minimum coverage of Torrent Variant 
Caller high stringency settings to 10x and made a custom parameter setting. The custom 
parameters are shown in Table 2.10.1. In addition, as mentioned earlier, the homopolymer 
region of more than four-mer, were excluded. Using this settings and after exclusion of 
homopolymer regions, 1538 variants were found. From this number, 353 were newly found and 
had no entry in dbSNP 138. 
3.5 Validation of the consistency of genotypes found using deep sequencing 
To validate the consistency of variant detection by deep sequencing method, we have used four 
previously genotyped SNP positions which were also in our target region. This analysis was 
performed by our collaborators in Bonn (Parmar et al. 2013). These positions were analyzed by 
KASPar single nucleotide polymorphism genotyping system (KBioscience, Hoddesdon, UK) using 
a real-time PCR system. These SNPs were rs2227983 in EGFR gene and rs1130214, rs1130233 and 
rs3730358 in AKT1 gene. After comparison we have found only one discrepancy in rs2227983. A 
single patient has been detected to be heterozygote by KASPar method but found to be 
homozygote variant by deep sequencing at this position. The genotypes regarding this position 
in other samples and other three positions genotyped were identical comparing two genotyping 
methods. 
Table 3.5.1 Consistency of genotyping by deep sequencing tested by previously genotyped positions. Genotypes regarding four 
SNPs: rs2227983, rs1130214, rs1130233 and rs3730358 were compared. 
SNP rs2227983 rs1130214 rs1130233 rs3730358 
Total number of comparisons 126 126 126 126 
Number of mismatches 1 0 0 0 
 
In addition, as ARAF gene is localized in chromosome X, all the heterozygote variations must 
have occurred in female patients. We used the 8 genotyped ARAF variations for checking the 
gender of the patients. There were no mismatches found in this survey. 
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3.6 Frequency of SNPs’ missing calls in our sample population. 
Of 139 genotyped patients’ DNA samples, phenotypic data was available for 126 patients. Other 
samples were excluded from further analysis. To analyze the SNPs for their associations with 
phenotypes, we chose the SNPs which had more than or equal to 50% present calls (less than 
50% missing calls) in the sample population. Of all found SNPs only 1437 were qualified. 
Histograms of missing genotypes are shown in Figure 3.6.1. Mean number of no calls was 6.49 




3.6.1 Hardy-Weinberg equilibrium 
Allele frequencies were then subjected to Hardy-Weinberg equilibrium (HWE) testing.  Nineteen 
SNPs were then marked because their allele distribution was out of HWE. Marking was performed 
to report it in case of presenting these variations’ association with phenotypes. 
  
Figure 3.6.1 Histograms of missing (or No calls) among the SNPs. We have analyzed 126 patients and overall, we have identified 
1437 Variants. The Y axis represents the number of positions. The X axis represents the percent of no calls in each position. As 




3.6.2 Minor allele frequency (MAF) of the SNPs  
In this study average MAF was 8.79%. Figure 3.6.2 shows a histogram of MAF percentages 
categorized by the novelty of SNPs. Six hundred and fifty one (45%) SNPs had less than 1% MAF 
(rare SNPs) and the SNPs with less than 5% were 936 (65%). Three hundred and seventeen (22%) 
novel SNPs were found. Mean MAF of novel SNPs was 0.46% (ranging 0.40%-1.98%). MAF of 
exonic SNPs categorized by their functionality (data from SIFT software) are displayed in 
Figure 3.6.3. Total number of coding SNPs was 103 of which 68 were synonymous and 38 were 
nonsynonymous. Average MAF of noncoding SNPs was 9.02% while average MAF of coding SNPs 
Figure 3.6.2 Minor allele frequencies (MAF) of SNPs categorized by novelty of SNPs. As displayed above, all of the frequent 
SNPs were already recorded in the databases while the very rare variants were new. The number of singleton variant was 
560. The number of variants with less than 1% MAF was 651. 
75 
 
was 6.15%. Average MAF of synonymous and nonsynonymous SNPs were 8.04% and 3.34% 
respectively. Only one nonsense SNP was found in MTOR with the MAF of 1.60%.  
 
 
Figure 3.6.3 Minor allele frequency of all exonic SNPs (n= 113, 7.9% of total variations found) categorized by their effect. 
Categorization is done by SIFT software. 
 
3.7 Functionality of genetic variants  
Functionality of the variants was predicted by SIFT which is one of the most frequently used 
bioinformatics tools. According to this prediction, the SNPs were categorized into noncoding, 
synonymous, single amino acid change and nonsense.  
The EGFR gene was completely sequenced; therefore the highest number of SNPs was found in 
this gene. Of 913 variants found in EGFR gene region, 212 SNPs were novel. Out of novel SNPs 
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only 1 caused a single amino acid substitution and had a MAF of 0.4%. MTOR had the second 
highest number of variations followed by AKT1 gene. Forty eight variants were found in MTOR. 
Four of MTOR variations cause amino acid substitution; while 1 deleterious amino acid 
substitution was predicted by both SIFT and Provean. Prediction of effects of amino acid 
exchanging variants was performed by Provean and SIFT prediction softwares. The result of this 
prediction is summarized in Table 3.7.1. Although 38 variants were found in AKT1; no amino acid 
substitution variation has been found. CXCR2, NFKB1 and RPS6KB2 wielded 4 amino acid 
substitution variations which was the highest number among genes. Mean minor allele 
frequencies of these variations were 0.6%, 0.4% and 1.7% in CXCR2, NFKB1 and RPS6KB2 genes 
respectively. Number of variations in each 1000 bp of targeted region is shown in Figure 3.7.1. 
Highest variation ratio was found in MAP2K2, followed by RPS6KB2 and EGFR. MAP2K2 – as the 
highest – had about 6 variations in 1000 bp. On the other hand, PTEN with 0.7 variations had the 
lowest variation ratio. 
Table 3.7.1 Number of variants categorized by their effect (noncoding, synonymous, single amino substitution). Only 1 premature 
stop-codon variant existing in dbSNP 138 was found in MTOR gene which is not shown in this table. 





Existing in dbSNP 138 Novel 
    Ncod. NonSyn. Syn. Ncod. NonSyn. Syn. 
The 
receptor 
EGFR 196300 913 688 2 11 209 1 2 







AKT1 8423 38 32 0 3 3 0 0 
AKT2 10291 32 22 2 2 6 0 0 
AKT3 9384 20 10 0 0 10 0 0 
MTOR 16138 48 28 2 8 6 2 2 
PIK3CA 6201 15 10 1 3 1 0 0 
PIK3CB 7060 12 8 0 0 3 1 0 
PIK3R1 12762 37 28 2 4 2 1 0 
PIK3R2 8439 17 8 1 5 2 1 0 
PTEN 7106 5 2 0 1 2 0 0 
RPS6KB1 7916 10 8 0 0 2 0 0 
RPS6KB2 3996 20 8 3 1 6 1 1 








ARAF 4444 5 5 0 0 0 0 0 
BRAF 5146 9 8 0 1 0 0 0 
HRAS 2228 5 2 0 0 2 0 1 
KRAS 7873 25 21 1 1 2 0 0 
MAP2K1 4702 16 16 0 0 0 0 0 
MAP2K2 4419 27 13 1 3 10 0 0 
MAPK1 7330 24 16 0 2 4 2 0 
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Existing in dbSNP 138 Novel 
    Ncod. NonSyn. Syn. Ncod. NonSyn. Syn. 
MAPK3 4112 11 8 0 1 2 0 0 
NRAS 5554 11 7 0 1 2 1 0 
RAF1 5825 22 12 0 1 8 1 0 




















 NFKB1 8640 26 16 4 2 3 0 1 
NFKB2 6538 19 12 0 2 3 1 1 
REL 4085 6 5 0 0 1 0 0 
RELA 4897 12 9 2 0 0 1 0 
RELB 3879 16 10 0 2 3 1 0 




















 CXCR1 3503 6 2 4 0 0 0 0 
CXCR2 4718 14 7 2 3 1 1 0 
IL8 2505 2 2 0 0 0 0 0 
Nonsyn.: nonsynonymous amino acid substitution; Ncod.: noncoding; Syn.: Synonymous. 
 
Figure 3.7.1 Number of variations in 1000 bp of targeted region categorized by genes. As well as total number of variations, 



































































































































All variations Nonsyn. Variations
                                PI3K/Akt                                                      Ras/MAPK         Inflammatory response regulators      Cytokines 
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Table 3.7.2 Function prediction of effects of nonsynonymous SNPs. Prediction tools used are explained in methods section 2.11. 
 Chr Position Gene 
name 
ID Codon change aa 
substitution 









7 55233024 EGFR rs144943614 TGC [G/A]TC AAG V592I Tol Tol Dam 0.004 
7 55229255 EGFR rs2227983 CCC A[G/A]G GAC R521K Tol Tol Tol 0.272 
7 55231472 EGFR  CAC [C/A]CA GAG P560T Dam Dam Tol 0.004 







19 40739513 AKT2 rs33933140 GAG A[T/C]T CAG I136T Tol Dam --- 0.420 
19 40745923 AKT2 rs12980468 CAG T[G/A]T GAG C223Y Dam Tol --- 0.004 
3 138384011 PIK3CB  GAT [C/T]GC TCT R847C Dam Dam Dam 0.004 
3 178927410 PIK3CA rs2230461 GAT AT[A/G] TAC I391M Tol Tol Tol 0.056 
5 67569229 PIK3R1 rs367923318 CTC [C/A]CG GAT P116T Tol Dam Dam 0.004 
5 67588148 PIK3R1 rs3730089 AAT AT[G/A] TCC M326I Tol Tol Tol 0.122 
5 67588351 PIK3R1  GAA C[T/C]G GAA L13P Tol Dam --- 0.004 
19 18271881 PIK3R2  GAC [G/A]TG GAT V162M Tol Dam Dam 0.004 
19 18273047 PIK3R2 rs1011320 GCC [T/C]CC ACA S313P Tol Tol Tol 0.025 
1 11186750 MTOR  ATT C[G/A]C ATT R2152H Dam  Dam Tol 0.004 
1 11199647 MTOR rs144984370 CCT CA[T/G] GAA H1647Q Tol Tol Dam 0.004 
1 11308007 MTOR rs35903812 AAT [G/A]CC TTG A329T Tol Tol Tol 0.004 
1 11319413 MTOR  AGC AA[T/G] GTG N18K Tol Tol Tol 0.004 
11 67200123 RPS6KB2  ATA C[G/A]G CCT R121Q Tol Dam --- 0.004 
11 67200812 RPS6KB2 rs55987642 TCG C[C/T]G CCC P267L Dam Tol Dam 0.056 
11 67201490 RPS6KB2 rs200667089 CAG [C/T]GG ATT R311W Dam Dam Dam 0.004 
11 67202519 RPS6KB2 rs374535834 CCC A[C/T]G GAG T443M Tol Tol Tol 0.004 







 12 25368380 KRAS rs201170656 ATA [A/C]TG  M189L Tol Tol Tol 0.005 
19 4097323 MAP2K2 rs151133017 AGC C[G/A]G CCT R313Q Tol Tol Dam 0.004 
22 22123569 MAPK1  TTG [GA/TC]T GAC  D336S Dam Dam Dam 0.004 
1 115251173 NRAS  TTG [C/T]CA TGT P185S Tol Tol Tol 0.004 
3 12647779 RAF1  ACT [A/G]TT GGT I201V Tol Tol Tol 0.004 





















4 103518700 NFKB1 rs4648072 GCT [A/G]TG CAG M507V Tol Tol Tol 0.004 
4 103518782 NFKB1 rs150281816 CAG C[G/A]C CAT R534H Dam Dam Dam 0.004 
4 103527745 NFKB1 rs149211506 CGC TT[G/T] GGT L615F Tol Tol Tol 0.004 
4 103533226 NFKB1 rs201233299 AAA C[C/G]A TAT P793R Tol Tol Dam 0.004 
10 104161516 NFKB2  TCA [C/T]TT GGT L770F Tol Dam Dam 0.004 
11 65421964 RELA rs369008511 CCA G[C/G]T CCT A511G Tol Dam Tol 0.004 
11 65425764 RELA rs61759893 CCA [G/A]AT ACA D288N Dam Tol Dam 0.004 
11 65427175 RELA  CTC C[G/A]C CTG R171H Tol Tol Dam 0.004 
19 45540956 RELB  ACC [G/A]CC AGC A550T Tol Dam Dam 0.004 





















2 219028932 CXCR1 rs16858808 CAT [C/T]GT GTT R335C Dam Tol Dam 0.024 
2 219029108 CXCR1 rs2234671 GAG A[G/C]C TGT S276T Tol Tol Tol 0.061 
2 219029843 CXCR1 rs16858811 TGT A[T/G]G CTA M31R Tol Tol Tol 0.028 
2 219029932 CXCR1 rs55808468  AT[G/A] TCA M1I Tol Tol Tol 0.004 
2 218999666 CXCR2  AAC [A/C]AG TAT K48Q Tol Tol Dam 0.004 
2 219000230 CXCR2 rs10201766 CTG [C/T]GT ACG R236C Dam Tol Tol 0.008 
2 219000267 CXCR2 rs61733609 CAC C[G/A]G GCC R248Q Dam Dam Dam 0.008 
Tol stands for tolerated, meaning without major effect on protein function expected and Dam stands for damaging with major 
effects on protein function expected. The algorithms for protein function prediction were Provean (Choi et al. 2012), SIFT (Kumar 
et al. 2009), and Polyphen2 (Adzhubei et al. 2010). 
As shown in Table 3.7.2, from a total of 41 non-synonymous amino acid substitutions, 30 
occurred only once in a heterozygous state and 2 occurred twice. Six SNPs occurred less than 15 
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and more than 5 times in a heterozygous state (MAF of 1% to 5%). Two of these three SNPs 
occurred once in heterozygote state and one occurred only once.  
Twenty six variants were predicted to be damaging using at least one of the prediction tools 
Table 3.7.2. According to consistent bioinformatics predictions from all three of Provean, SIFT, 
and Polyphen2 there were only 4 variants which were predicted to be associated with a loss of 
function by all three algorithms. Regarding the variants which also occurred in homozygote state, 
two were predicted to be tolerated by all three of tools and only one was predicted to be 
damaging by Provean (AKT2, I136T amino acid substitution). Eight amino acid substitutions were 
predicted to be damaging by two of out of three tools. Of these variations, except for RPS6KB2 
P267L which had the MAF of 0.056, others only happened once. 
 
3.8 Runs of homozygosity 
While screening the minor allele frequencies of rare variants, we surprisingly found several rare 
variants which occurred in homozygous form. By visualizing these variations we have found that 
some of these rare SNPs occurred in one patient. Surveying the genotypes of this patient we 
found a region with runs of homozygosity (ROH) in patient 278 (Figure 3.8.1) at the gene locus 
coding for the EGFR. In the patient with the ROH we did not find even a single heterozygous 
variant in the EGFR region. A histogram of heterozygous genotype counts are shown in Figure 
3.8.2. However other patients had at least 31 heterozygous genotypes at this region (On average, 
106 heterozygous variants were found among the patients).  
The coverage at this region was also investigated to estimate the quality at this position. 
Furthermore genotypes of other subjects with similar coverage at this region were investigated. 
Several heterozygous genotypes were found in patients with similar coverage in the EGFR region.  
We have determined if there were any particular phenotypes in subject 278 due to the ROH. 
Maximum skin rash in this patient was grade 1 (apparently not much different from the total 
sample mean of 1.2). Diarrhea did not occur in this patient (total sample mean 0.6) and the 
survival time was only 111 days after treatment start date (total sample mean 234). This patient 
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was enrolled in this study having grade IIIa of bronchial cancer and received erlotinib. 
 
Figure 3.8.1 Runs of homozygosity. Using the integrative genomic viewer it is displayed here that patient number 278 shows no 
heterozygous genotypes. Gray lines represent regions with homozygous reference genotypes. Dark and light blue lines represent 
heterozygous and homozygous variant genotypes, respectively. EGFR gene region is displayed. 
 
 
Figure 3.8.2 Histogram of heterozygous genotype counts in the present study. Sample 278 had no variations which is an outlier 




3.9 Association of SNPs with skin rash  
3.9.1 First analysis phase: Genomic variants predisposing to skin rash 
Twenty six variants were found to have an association with the existence of level 1 or greater 
skin rash using a genotypic test, using the conventional 0.05 type-I-error without adjusting for 
multiple testing. However, none of these SNPs achieved significance after correction for multiple 
testing (level of significance considering 1437 variation is 0.000035). The Manhattan plot of this 
association is shown in Figure 3.9.1. The intronic EGFR variant rs73420732 had the lowest P value 
(0.0013) in the genotypic test as well in the allelic test (0.0015). This SNP was in LD with 4 other 
significant EGFR SNPs namely: rs57620875, rs7784637, rs28557040 and rs17335759 while 
considering a r2>0.4 as cutoff level, all these 4 other SNPs were also in intron 1. The LD plot of 
these SNPs is shown in Figure 3.9.2 . A SNP in EGFR-AS1 (EGFR antisense RNA 1, rs17290461) which 
overlaps with the EGFR gene was also associated with lack of skin rash.  
A zoomed-in association plot for EGFR gene is shown in Figure 3.9.2. From the significant EGFR 
SNPs five sets of linked ones were identified with r2>0.4 as cutoff level. First set includes the 
rs73420732, rs57620875, rs7784637, rs28557040 and rs17335759 localized in intron 1. Other 
sets were rs2293348, rs940810, and rs9692301 along with SNPs rs1468727 and rs4947984 as 
another set; as well as two other sets rs6970262 and rs1404908 besides rs7796872 and 
rs10488141. These SNPs were all localized in noncoding regions. 
Figure 3.9.1 Manhattan plot of association of SNPs found in this study and the presence of skin rash grade ≥1.  P value of Fisher’s 
exact test was used for making this plot by Plink software. –log10 (0.05, the level of significance) equals 1.30 and is shown by 




In the order of decreasing significance, the fourth significant SNP was rs79397497 in PIK3R1 gene 
(P value = 0.012). This 3’ UTR SNP was linked to the other PIK3R2 significant SNP rs3729984 which 
was also in the 3’ UTR region. 
Two linked SNPs in AKT1 gene (both in intron 1) were significantly associated to the presence of 




Table 3.9.1 Germline SNPs associated with presence of skin toxicity of level 1,2 or 3 with P value < 0.05. SNPs with significant allelic 
test associations are also shown in this table. Colors represent the linkage between variations. Colors of EGFR variant correspond 
to the colors used in Figure 3.9.2. 
a, Homozygote reference genotype/Heterozygotes/Homozygote variant genotype; b, Minor allele/reference allele;* 
P values were calculated using Fisher’s exact test 
SNP Region Genotype based analysis Allele based analysis 
Gene name dbSNP ID  No rash 
groupa 





EGFR rs73420732 21/4/0 99/0/0 1.4E-03 46/4 198/0 1.5E-03 
EGFR rs57620875 21/3/0 98/0/0 6.9E-03 45/3 196/0 7.2E-03 
EGFR rs7784637 22/3/0 101/0/0 7.1E-03 47/3 202/0 7.4E-03 
PIK3R1 rs79397497 14/6/0 85/6/1 1.2E-02 34/6 176/8 2.2E-02 
EGFR rs7781264 17/5/1 39/49/10 1.3E-02 39/7 127/69 8.1E-03 
AKT1 rs61757057 21/3/1 98/2/0 1.5E-02 45/5 198/2 4.1E-03 
AKT1 rs61757056 21/3/1 96/2/0 1.5E-02 45/5 194/2 4.4E-03 
EGFR rs28557040 20/5/0 95/4/0 1.6E-02 45/5 194/4 1.8E-02 
PIK3R1 rs3729984 17/6/0 92/6/1 1.7E-02 40/6 190/8 3.0E-02 
EGFR rs6970262 10/6/7 32/55/12 1.7E-02 26/20 119/79 7.4E-01 
EGFR rs41367446 16/3/0 81/1/0 2.0E-02 35/3 163/1 2.2E-02 
MAP2K2 rs6630 18/1/2 83/13/0 2.2E-02 37/5 179/13 3.3E-01 
PIK3R1 rs3730089 17/1/1 68/24/0 2.2E-02 35/3 160/24 5.9E-01 
EGFR rs17335759 20/3/0 95/1/0 2.3E-02 43/3 191/1 2.4E-02 
KRAS rs61764367 20/4/0 95/3/0 2.7E-02 44/4 193/3 2.9E-02 
EGFR rs2293348 11/7/5 44/49/5 2.8E-02 29/17 137/59 3.8E-01 
EGFR rs1468727 7/13/0 59/31/6 2.8E-02 27/13 149/43 2.2E-01 
EGFR rs17290461 22/2/0 100/0/0 3.6E-02 46/2 200/0 3.7E-02 
EGFR rs78134465 22/2/0 100/0/0 3.6E-02 46/2 200/0 3.7E-02 
EGFR rs1404908 9/7/7 33/50/10 3.8E-02 25/21 116/70 3.2E-01 
RPS6KB2 rs201739335 23/2/0 100/0/0 3.9E-02 48/2 200/0 3.9E-02 
EGFR rs4947984 24/0/0 85/16/0 4.0E-02 48/0 186/16 4.7E-02 
EGFR rs4947965 11/6/3 40/42/2 4.1E-02 28/12 122/46 8.5E-01 
EGFR rs10234806 6/12/1 55/31/4 4.2E-02 24/14 141/39 6.1E-02 
EGFR rs940810 13/6/4 45/36/3 4.6E-02 32/14 126/42 4.6E-01 
EGFR rs9692301 9/6/5 37/42/6 4.6E-02 24/16 116/54 3.5E-01 
AKT2 rs33933140 12/11/1 29/45/21 5.4E-02 35/13 103/87 2.2E-02 
EGFR rs7796872 15/7/2 80/20/1 6.1E-02 37/11 180/22 3.4E-02 
EGFR rs6947531 5/7/11 32/45/22 6.2E-02 17/29 109/89 3.3E-02 
KRAS rs1137188 1/8/6 18/47/11 6.3E-02 10/20 83/69 4.5E-02 
EGFR rs4140770 13/4/1 37/43/10 6.4E-02 30/6 117/63 3.2E-02 
MAPK1 rs13515 17/3/0 51/31/4 9.7E-02 37/3 133/39 2.9E-02 
EGFR rs10488141 12/8/2 75/20/4 1.0E-01 32/12 170/28 4.3E-02 




Figure 3.9.2 Association plot and LD of EGFR SNPs and existence of rash. A) Five sets of EGFR SNPs were associated to rash of 
grade 1 or higher. The lowest P value belonged to rs73420732 which was in LD with rs57620875, rs7784637, rs28557040 and 
rs17335759. This set is shown in red. Other sets are as follows: rs6970262 and rs1404908: black; rs2293348, rs940810, 
rs9692301: green; rs1468727 and rs4947984: brown; rs7796872 and rs10488141: blue; B) LD plot of rs73420732; SNP with the 
lowest P value for association to existence of skin rash. Four other significantly associated SNPs were in LD with this SNP namely 
























3.9.2 Second analysis phase: Genomic variants predisposing to high grade skin rash 
We have also surveyed the association of high grade rash (grade 2 or higher) with the identified 
variations. Twenty eight SNPs had P value < 0.05 using Fisher’s exact test. The Manhattan plot of 
SNPs’ association to high grade rash is shown in Figure 3.9.4. The lowest P value (0.0012) belonged 
to rs131515 in 3’ UTR region of MAPK1 gene located on chromosome 22. Four other SNPs in 
MAPK1 gene were significantly associated with high grade rash using an allelic test namely: 
rs6928 (3’ UTR), rs9607340 (upstream of the gene), rs9340 (3’ UTR), and rs13943 (3’ UTR). These 
4 SNPs were in LD; however, they were not linked to the SNP with lowest P value (Figure 3.9.3). 
Table 3.9.2 demonstrates the SNPs with highest significance level. Two EGFR SNPs rs6593202 and 
rs17335891 had the second and third lowest P values of 0.0042 and 0.0079 respectively. A 
zoomed-in association plot for EGFR gene is shown in Figure 3.9.5. Two sets of EGFR gene SNPs 
were found among the significantly association SNPs: rs4947965, rs11773818, and rs11766798 
were linked; as well as SNPs rs62459768 and rs6593207. Both of these sets are localized in the 
intron 1. Significant SNPs were also found in AKT1 (rs45598737), MAP2K2 (rs17851657), NFKB1 
(rs72696119), AKT3 (rs14403), BRAF (rs3789806), KRAS (rs1137188 and rs712), AKT2 
(rs33933140), and PIK3R1 (rs171649) genes. 
Figure 3.9.3 Linkage Disequilibrium plot of significant SNPs in MAPK1 
gene. rs13515 has the highest association with skin rash grade 2 or 
higher. rs6928, rs9607340, rs9340, and rs13943 were linked together 
but not to the most significant SNP. r2 values. Black square represents 
r2 of 100. 
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Table 3.9.2 Germline SNPs associated with presence of skin toxicity of level 2 and 3 with P value < 0.05. SNPs with significant 
allelic test associations are also shown in this table. Colors represent the linkage between variations. Colors of EGFR variant 
correspond to the colors used in Figure 3.9.5. 
SNP Region Genotype based analysis Allele based analysis 









MAPK1 rs13515 21/22/3 47/12/1 1.18E-03 64/28 106/14 8.81E-04 
EGFR rs6593202 33/18/2 60/10/0 4.22E-03 84/22 130/10 2.07E-03 
EGFR rs17335891 17/30/1 38/23/6 7.88E-03 64/32 99/35 2.43E-01 
AKT1 rs45598737 38/13/0 65/5/1 8.21E-03 89/13 135/7 3.40E-02 
EGFR rs4947965 16/28/1 35/20/4 1.14E-02 60/30 90/28 1.60E-01 
EGFR rs11773818 18/29/1 38/23/6 1.31E-02 65/31 99/35 3.75E-01 
EGFR rs4947488 18/29/1 38/23/6 1.31E-02 65/31 99/35 3.75E-01 
EGFR rs6970262 15/34/4 27/27/15 1.34E-02 64/42 81/57 8.95E-01 
EGFR rs3800827 19/28/1 38/21/6 1.35E-02 66/30 97/33 3.69E-01 
EGFR rs11766798 19/28/1 38/22/6 1.46E-02 66/30 98/34 3.74E-01 
EGFR rs2280653 37/15/0 58/9/5 1.51E-02 89/15 125/19 8.52E-01 
EGFR rs9642564 22/30/1 40/22/6 1.60E-02 74/32 102/34 3.86E-01 
MAP2K2 rs17851657 34/11/5 48/22/0 1.77E-02 79/21 118/22 3.10E-01 
EGFR rs62459768 41/12/0 64/5/1 1.77E-02 94/12 133/7 9.03E-02 
EGFR rs6593207 34/19/0 60/12/1 2.03E-02 87/19 132/14 6.00E-02 
EGFR rs12668421 21/30/1 41/25/6 2.33E-02 72/32 107/37 3.92E-01 
EGFR rs79198232 52/1/0 61/10/1 2.39E-02 105/1 132/12 8.74E-03 
EGFR rs6956366 14/34/5 33/28/10 2.42E-02 62/44 94/48 2.33E-01 
EGFR rs56208956 37/10/1 65/5/0 2.44E-02 84/12 135/5 1.84E-02 
NFKB1 rs72696119 16/11/4 12/30/11 2.91E-02 43/19 54/52 2.37E-02 
EGFR rs1404908 16/30/3 26/27/14 2.95E-02 62/36 79/55 5.86E-01 
EGFR rs11760406 21/22/1 40/17/6 3.15E-02 64/24 97/29 5.21E-01 
AKT3 rs14403 33/18/0 34/27/7 3.17E-02 84/18 95/41 3.35E-02 
EGFR rs6978771 21/27/1 41/22/5 3.33E-02 69/29 104/32 3.65E-01 
BRAF rs3789806 29/18/1 50/11/1 3.82E-02 76/20 111/13 3.75E-02 
KRAS rs1137188 11/25/3 8/30/14 4.06E-02 47/31 46/58 3.67E-02 
EGFR rs76138885 44/6/0 68/1/0 4.06E-02 94/6 137/1 4.36E-02 
EGFR rs6947902 30/19/3 54/12/6 4.11E-02 79/25 120/24 1.96E-01 
EGFR rs17172446 39/7/4 42/24/5 4.39E-02 85/15 108/34 1.05E-01 
EGFR rs12535226 8/32/9 24/30/14 4.58E-02 48/50 78/58 2.32E-01 
EGFR rs723526 31/19/3 54/12/6 4.64E-02 81/25 120/24 1.98E-01 
MAPK1 rs6928 21/24/5 18/31/18 4.70E-02 66/34 67/67 1.65E-02 
EGFR rs12673110 15/31/7 34/27/7 4.90E-02 61/45 95/41 5.81E-02 
MAPK1 rs9607340 21/22/6 17/31/18 6.17E-02 64/34 65/67 1.62E-02 
MAPK1 rs9340 8/27/11 21/26/8 6.46E-02 43/49 68/42 3.44E-02 
KRAS rs712 15/25/5 11/35/16 6.65E-02 55/35 57/67 3.74E-02 
AKT2 rs33933140 11/25/12 30/31/10 6.77E-02 47/49 91/51 2.32E-02 
EGFR rs7796872 45/8/0 50/19/3 7.79E-02 98/8 119/25 2.43E-02 
EGFR rs4947963 15/23/5 34/24/3 8.50E-02 53/33 92/30 4.59E-02 
MAPK1 rs13943 21/24/6 18/33/17 9.63E-02 66/36 69/67 3.50E-02 
PIK3R1 rs171649 21/25/6 19/34/18 1.03E-01 67/37 72/70 3.75E-02 
EGFR rs980653 42/10/0 49/20/4 1.13E-01 94/10 118/28 4.87E-02 
AKT2 rs2304189 30/18/3 29/27/11 1.30E-01 78/24 85/49 3.40E-02 
a, Homozygote reference genotype/Heterozygotes/Homozygote variant genotype; b, Minor allele/reference allele; P 







Figure 3.9.4 Manhattan plot of association of SNPs found in this study and the presence of skin rash grade ≥2.  –log10 (0.05, 
level of significance) equals 1.30 and is shown by the black horizontal line. P value of Fisher’s exact test was used for making 
this plot. 
Figure 3.9.5 Association plot of EGFR SNPs and existence of high grade rash. Two sets of EGFR SNPs were associated to rash of 
grade 2 or higher. These sets are: rs4947965, rs11773818, and rs11766798: red; rs62459768 and rs6593207: green. Both of 






















3.10 Gene-based and pathway-based analyses 
Gene-based and pathway-based analyses were performed using the PSEQ software. The 
variations which were analyzed in this analysis were damaging variants found by any of the three 
(SIFT, Polyphen2 or Provean) variant effect prediction tools and had minor allele frequency of 
less than 5%. Considering these criteria 23 variations were eligible to this analysis. The gene 
burden test, the C-alpha test, the frequency-weighted test, the variable threshold test, the UNIQ 
and summary statistics tests were performed. 
In pathway-based analysis with dichotomization of the skin rash phenotype as any grade vs. no 
rash, an association was found between PI3K/Akt pathway variations using C-alpha and summary 
statistics tests (P values 0.03 and 0.04, respectively). Among 8 variations considered in this 
pathway 4 singletons were found in skin rash group and 4 other were found in no rash group. As 
these tests are permutation-based a minimum P value possible (the I value) is also calculated for 
each test. In case of PI3K/Akt pathway this value for both C-alpha and summary statistics was 
0.002. 
In gene-based analysis (using genes as units of comparison) an association has not been found 
while using either one of skin rash phenotype dichotomization strategies. The significance level 
was calculated 0.0017 after correction for multiple testing. However, none of the I values 
(representing the minimum P value possible considering sample size and number of variants) has 
reached this level.  
Table 3.10.1 Pathway-based association analysis. Both skin reaction related phenotype dichotomizations are shown in this table. 
Values are reported using gene burden test. 
 Number of 
variations 
considered 
P value I value Description 
case to 
control  
Skin rash grade 0 compared to 1-3     
     
PI3K/Akt + EGFR 10 1 0.20 6/4 
PI3K/Akt 8 0.83 0.20 4/4 
Ras/MAPK +EGFR 4 0.71 0.67 4/0 
Ras/MAPK 2 0.36 0.67 2/0 
Inflammatory response regulators  7 0.83 0.40 5/2 
Chemokines 4 0.58 0.27 8/3 
89 
 
 Number of 
variations 
considered 
P value I value Description 
case to 
control  
Inflammatory response regulators + 
Chemokines 
11 0.83 0.20 13/5 
All pathways 23 0.99 0.01 21/9 
     
Skinrash grades 0-1compared to 2-3     
     
PI3K/Akt + EGFR 10 0.83 0.20 4/6 
PI3K/Akt 8 1 0.40 2/6 
Ras/MAPK +EGFR 4 0.47 0.19 2/2 
Ras/MAPK 2 0.83 0.20 0/2 
Inflammatory response regulators  7 1 0.20 1/6 
Chemokines 4 1 0.40 3/8 
Inflammatory response regulators + 
Chemokines 
11 1 0.20 4/14 
All pathways 23 0.80 0.07 8/22 
 
3.11 Diarrhea as another side effect 
Four EGFR SNPs had the smallest P values in the analysis for association with existence of diarrhea 
(equal or more than grade 1) as another side effect. Three of these SNPS (rs11770531 rs11770689 
and rs11760524) are positioned in EGFR intron 6 and one (rs940806) is located downstream of 
the EGFR gene in an intergenic region. A variation in 3’UTR region of NRAS gene (rs14804) and 
two intronic NFKB1 SNPs were also significantly associated with diarrhea. However none of these 
variations reached the significance level when the P value was adjusted by the number of SNPs.  
 
Table 3.11.1 Ten most significant germline SNPs associated with existence of diarrhea using Fisher’s exact test. 
Chr. Chromosome; a, Homozygote reference genotype/Heterozygotes/Homozygote variant genotype; b, Minor 
allele/reference allele; 
SNP Region Genotype based analysis Allele based analysis 
Gene 
name 











EGFR rs11770531 7p11.2 55220905 T/C 41/2/1 61/19/0 3.56E-03 84/4 141/19 6.79E-02 
EGFR rs11770689 7p11.2 55221469 T/C 37/1/1 57/15/0 6.15E-03 75/3 129/15 1.22E-01 
EGFR rs940806 7p11.2 55279745 A/G 20/17/6 15/49/13 8.52E-03 57/29 79/75 2.98E-02 
EGFR rs11760524 7p11.2 55221167 G/A 41/3/1 61/19/0 1.31E-02 85/5 141/19 1.21E-01 
NRAS rs14804 1p13.2 115249843 A/G 20/10/1 21/33/9 1.36E-02 50/12 75/51 4.97E-03 
EGFR rs62459767 7p11.2 55198347 T/C 40/1/0 64/15/1 1.37E-02 81/1 143/17 7.98E-03 
NFKB1 rs3817685 4q24 103534560 G/C 24/19/1 31/31/15 1.58E-02 67/21 93/61 1.62E-02 
NFKB1 rs4648050 4q24 103514741 C/T 19/18/1 26/31/15 2.23E-02 56/20 83/61 1.95E-02 
EGFR rs2740764 7p11.2 55267458 G/T 29/12/2 34/41/3 2.31E-02 70/16 109/47 6.58E-02 





3.12 Survival and effect sizes in carriers of non-synonymous variants 
It is well known, that skin rash is related to survival in patients receiving EGFR inhibition therapy. 
Concerning survival, it was not possible to perform statistical testing for significance with most 
of the rare variants. However, it may still be informative to present the mean days of survival in 
carriers of the amino acid substitution variants. This is presented in Table 3.12.1.  
The majority of nonsynonymous variations occurred in the PI3K/Akt pathway. Among them two 
amino acid substitutions in RELA (D288N) and RAF1 (I201V, a novel variation) both occurring in 
one certain patient were associated with a very low survival (29 days). Other amino acid 
substitution variations in MTOR (H1647Q) and RPS6KB2 (T443M) were as well associated with a 
low survival time (19 and 35 days respectively). Nevertheless all of these variations were rare 
variations and the association with short survival does not proof causality. 
Considering survival time, patients with the PIK3R1 exon 8 M326I variation show a trend for a 
better survival for carriers of the isoleucine amino acid. While mean survival time was 234 days 
in our study, heterozygote patients for PIK3R1 M326I variation (N=25) had 252 days and the 
homozygote patient had 314 days of survival time. Interestingly, this variation was also 
Figure 3.11.1 Manhattan plot of association of SNPs found in this study and the presence of diarrhea.  –log10 (0.05, level of 
significance) equals 1.30 and is shown by the black horizontal line. P value of Fisher’s exact test was used for making this plot. 
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associated to presence of skin rash. In concert with the association of survival and skin rash, 24 
out of 26 patients with this variation were affected with skin rash. 
Table 3.12.1 Survival time, skin rash and diarrhea in relation to the amino acid substitutions identified in my project. In the 
second row (total sample mean) mean of survival time, maximum skin rash grade, and maximum diarrhea grade from all 
patients is shown. 
 



















r EGFR V592I 1 Tol Tol Dam 1 360 2 2 
EGFR R521K 1 Tol Tol Tol 55 230 1.1 0.5 
    2    6 226 1.7 0.8 
EGFR P560T 1 Dam Dam Tol 1 360 2 1 







AKT2 I136T 1 Tol Dam --- 56 231.7 1.3 0.6 
  2    22 253 1.5 0.5 
AKT2 C223Y 1 Dam Tol --- 1 360 2 1 
PIK3CB R847C 1 Dam Dam Dam 1 360 1 0 
PIK3CA I391M 1 Tol Tol Tol 11 210.1 1.3 0.5 
PIK3R1 P116T 1 Tol Dam Dam 1 151 2 0 
PIK3R1 M326I 1 Tol Tol Tol 25 252.4 1.7 0.6 
  2    1 314 0 1 
PIK3R1 L13P 1 Tol Dam --- 1 360 0 0 
PIK3R2 V162M 1 Tol Dam Dam 1 360 0 1 
PIK3R2 S313P 1 Tol Tol Tol 6 280.7 1.5 1 
MTOR R2152H 1 Dam Dam Tol 1 360 2 1 
MTOR H1647Q 1 Tol Tol Dam 1 19 0 0 
MTOR A329T 1 Tol Tol Tol 1 233 0 0 
MTOR N18K 1 Tol Tol Tol 1 360 2 0 
RPS6KB2 R121Q 1 Tol Dam --- 1 360 1 0 
RPS6KB2 P267L 1 Dam Tol Dam 14 205.5 1.1 0.6 
RPS6KB2 R311W 1 Dam Dam Dam 1 100 0 4 
RPS6KB2 T443M 1 Tol Tol Tol 1 35 2 2 







 KRAS M189L 1 Tol Tol Tol 1 127 2 0 
MAP2K2 R313Q 1 Tol Tol Dam 1 144 1 0 
MAPK1 D336S 1 Dam Dam Dam 1 90 1 0 
NRAS P185S 1 Tol Tol Tol 1 360 1 0 
RAF1 I201V 1 Tol Tol Tol 1 29 0 1 





















NFKB1 M507V 1 Tol Tol Tol 1 106 1 0 
NFKB1 R534H 1 Dam Dam Dam 1 358 1 2 
NFKB1 L615F 1 Tol Tol Tol 1 360 1 0 
NFKB1 P793R 1 Tol Tol Dam 1 360 1 2 
NFKB2 L770F 1 Tol Dam Dam 1 358 1 2 
RELA A511G 1 Tol Dam Tol 1 193 1 0 
RELA D288N 1 Dam Tol Dam 1 29 0 1 
RELA R171H 1 Tol Tol Dam 1 278 1 0 
RELB A550T 1 Tol Dam Dam 1 90 2 0  
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CXCR1 R335C 1 Dam Tol Dam 6 185.8 1 0.7 
CXCR1 S276T 1 Tol Tol Tol 15 251.3 1.7 0.7 
CXCR1 M31R 1 Tol Tol Tol 7 172.1 1 0.6 
CXCR1 M1I 1 Tol Tol Tol 1 285 2 0 
CXCR2 K48Q 1 Tol Tol Dam 1 360 3 0 
CXCR2 R236C 1 Dam Tol Tol 2 220 0.5 1 
CXCR2 R248Q 1 Dam Dam Dam 2 227.5 1 0 
* 1 = heterozygous, 2: homozygous; survival time is presented in days, Tol stands for tolerated, meaning without major effect 
on protein function expected and Dam stands for damaging with major effects on protein function expected. The algorithms for 
protein function prediction were Provean (Choi et al. 2012), SIFT (Kumar et al. 2009), and Polyphen2 (Adzhubei et al. 2010) . 
 
To describe the possible effect of rare amino acid substitution variations, we have surveyed the 
survival, skin rash and diarrhea in the damaging variations with less than 5% minor allele 
frequency. A SNP was considered damaging when it was predicted to be damaging by any of the 
three prediction algorithms. As it is displayed in Table 3.12.2, when summarizing over all proteins 
we have not found a remarkable difference of phenotypes in carriers of these variations.  
Table 3.12.2 Survival, skin rash and diarrhea in carriers of variants predicted to be damaging. 






Total group 126 234.3 1.2 0.6 
All carriers with a variant predicted to be loss-of-function by 
Provean 
12 240.9 1.05 1.06 
All carriers with a variant predicted to be loss-of-function by 
SIFT 
14 266.2 1.07 0.79 
All carriers with a variant predicted to be loss-of-function by 
Polyphen2 
16 225.3 1.06 0.86 
All carriers with a variant predicted to be loss-of-function by all 
three tools 
4 261.4 0.75 1.5 
 
In addition, for better displaying the function of these variations we have identified the protein 
localization of nonsynonymous variations in Table 3.12.3. For this reason we have surveyed the 




Table 3.12.3 Functional domains and possible function of the protein domain in which the nonsynonymous variations are localized. 
Conservative changes are defined as when an amino acid is replaced by another amino acid with the same polarity or electric 
charge. CXCR proteins are chemokine receptors which have seven membrane spanning regions. The position of variations on CXCR 














EGFR Cons. V592I Furin-like cysteine rich domain, EGFR dimerization and 
signal transduction 
EGFR Cons. R521K Furin-like cysteine rich domain, EGFR dimerization and 
signal transduction 
EGFR Noncons. P560T Furin-like cysteine rich domain, EGFR dimerization and 
signal transduction 












AKT2 Noncons. I136T Linker region between PH(Pleckstrin Homology) domain and 
kinase domain, unknown effect 
AKT2 Noncons. C223Y Kinase domain, substrate phosphorylation  
PIK3CB Noncons. R847C Kinase domain, substrate phosphorylation 
PIK3CA Cons. I391M Membrane-binding domain (C2), Membrane recognition 
PIK3R1 Noncons. P116T Rho GTPase activating protein (RhoGAP), catalyzing the 
hydrolysis of GTP 
PIK3R1 Cons. M326I SH2(Src homology 2) domain,  interacting with 
phosphotyrosine-containing target peptides 
PIK3R1 Noncons. L13P SH3 (Sarc homology 3) domain, assembly of kinase Subunit 
PIK3R2 Cons. V162M RhoGAP, catalyzing the hydrolysis of GTP 
PIK3R2 Noncons. S313P Linker region between RhoGAP and SH2 domain 
MTOR Cons. R2152H Kinase domain, substrate phosphorylation 
MTOR Noncons. H1647Q Focal adhesion kinase (FAT) domain 
MTOR Noncons. A329T Armadillo type fold domain, Interaction with the rictor protein 
in the mTORC2 complex (regulation of Akt) 
MTOR Noncons. N18K ---* 
RPS6KB2 Noncons. R121Q Kinase domain, substrate phosphorylation 
RPS6KB2 Noncons. P267L Kinase domain, substrate phosphorylation 
RPS6KB2 Noncons. R311W Kinase domain, substrate phosphorylation 
RPS6KB2 Noncons. T443M Proline rich domain, binding to SH3 domains 








KRAS Cons. M189L The last amino acid, unknown effect 
MAP2K2 Noncons. R313Q Kinase domain, phosphorylation of ERK protein 
MAPK1 Noncons. D336S --- 
NRAS Noncons. P185S --- 
RAF1 Cons. I201V Linker region between two kinase domains 





















NFKB1 Cons. M507V Linker region between glycin rich domain and Ankyrin repeat 
domain 
NFKB1 Cons. R534H Linker region between glycin rich domain and Ankyrin repeat 
domain 
NFKB1 Cons. L615F Ankyrin repeat domain, NFKB inhibitor (IkBa) binds to this 
domain  
NFKB1 Noncons. P793R Linker region between Ankyrin repeat domain and death 
domain 








Functional domain or protein region, possible effects 
RELA Noncons. A511G --- 
RELA Noncons. D288N NF-kappa-B/Rel/Dorsal domain, protein dimerisation, DNA 
binding and nuclear localisation 
RELA Cons. R171H NF-kappa-B/Rel/Dorsal domain, protein dimerisation, DNA 
binding and nuclear localisation 
RELB Noncons. A550T --- 





















CXCR1 Noncons. R335C Cytoplasmic region of Chemokine receptor, G protein binding 
and catalyzing 
CXCR1 Cons. S276T Extracellular region of Chemokine receptor, acts as specific 
receptors for the CXCL8 
CXCR1 Noncons. M31R Extracellular region of Chemokine receptor, acts as specific 
receptors for the CXCL8 
CXCR1 Cons. M1I Extracellular region of Chemokine receptor, acts as specific 
receptors for the CXCL8 
CXCR2 Noncons. K48Q Extracellular region of Chemokine receptor, acts as specific 
receptors for the CXCL8 
CXCR2 Noncons. R236C Cytoplasmic region of Chemokine receptor, G protein binding 
and catalyzing 
CXCR2 Noncons. R248Q Cytoplasmic region of Chemokine receptor, G protein binding 
and catalyzing 
*The functional domain of some of variations were not identified because they were very close to either C or N 
terminal of the protein and their possible function has not been reported. 
 
 
As summarized in Table 3.12.3, 26 of the 41 amino acid substitutions were non-conservative 
replacements. Most of these variants could be assigned to known functional domains of the 
respective proteins. Of the 41 variations, 7 occurred in kinase domains and may cause the 
stoppage of the kinase cascade downstream of EGFR signaling pathway. However, which of these 









The development of targeted therapy has promised a new era in cancer therapy by improving 
response rates with less adverse effects on normal cells. The estrogen receptor (ER) in ER positive 
breast cancer was probably the first target for targeted cancer therapy and nowadays 
individualized therapy targeting the ER is widely used in ER positive breast cancer (Ward 1973). 
Typical side effects of chemotherapy such as bone marrow suppression, alopecia and mucositis 
are often less prevalent in targeted therapies and may even be absent in case of monotherapy. 
EGFR was targeted for the first time in 1983 by Mendelsohn’s group. They have developed an 
anti-EGFR antibody and successfully reduced the proliferation of EGFR bearing cancer cells both 
in vitro and in situ (against human tumor xenografts of squamous carcinoma cells and breast 
adenocarcinoma cells in athymic mice, both expressing EGFR) (Kawamoto et al. 1983, Masui et 
al. 1984a). However EGFR inhibition seems to have its own class of side effects such as skin 
toxicity. These side effects remarkably occur only in a subgroup of patients. Interestingly, the 
occurrence of skin toxicity has been proved to be correlated to drug response and survival rate 
in treated patients, but how much of this correlation is true or only due to confounding is still 
controversial (Petrelli et al. 2012). 
 
4.1 First analysis phase: Genomic variants predisposing to skin rash 
After exclusion of low quality sequences and erroneous variations, 1437 variants were included 
in the analysis in relation to skin toxicity. For the first analysis phase we dichotomized the patients 
by existence of skin rash phenotype into two groups: group of skin rash grade 0 and group of skin 
rash grades 1-3. As we had only 25 patients with no rash in the study population, number of 
variations in this group was relatively small. Therefore we tested the associations by Fisher’s 
exact test. In this phase of analysis, we found 27 associations (from 1437 tests) with a significance 
level of less than 0.05. However, correction for multiple testing considering 1437 variants would 
result in a level of 0.000035 which was reached by none of the variations.  
The most significant associations found in this phase were between 3 SNPs in EGFR gene and 
existence of skin rash. These 3 SNPs along with 2 other skin rash associated EGFR SNPs were 
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linked. All of them were positioned in intron 1 of EGFR gene on chromosome 7 between positions 
55094331 and 55099394. Intron 1 of EGFR gene is believed to be an important regulatory region 
for EGFR transcription (Gebhardt et al. 1999). EGFR transcription is tightly regulated and its 
overexpression is reported in several types of cancer and is associated with a poor prognosis. The 
promoter region of EGFR does not contain a TATA box. Upstream of the ATG start codon, there 
are four transcription factor SP1 binding sites positioned between -500 to -100 bases. There are 
two enhancer regions which are found upstream of the promoter region. In addition to these two 
upstream enhancer regions, two other enhancer regions are found in intron 1. One of them is 
located at +1788- +2318 position (Maekawa et al. 1989). The other enhancer region is localized 
1.1 kb downstream of the former mentioned enhancer region (McInerney et al. 2001) 
(Figure 4.1.1). This finding highlights the role of intron 1 in transcription regulation.  
 
Figure 4.1.1 Structure of 5’ sequence of EGFR gene. Four enhancer regions are shown as red boxes (Brandt et al. 2006). The CA 
repeat region which is believed to have a regulatory role in EGFR transcription is localized between exon 1 and first downstream 
enhancer region (Gebhardt et al. 1999). First 3 EGFR SNPs with the lowest P values are located 7kb (two SNPs and 10 kb 




























































































































Another feature in intron 1 is a CA sequence repeat which is also reported to have a regulatory 
role in transcription of EGFR (Gebhardt et al. 1999). The shorter repeat length was associated 
with higher transcription of EGFR gene. Up to 5 times lower levels of EGFR pre-RNA have been 
shown in vitro in samples with higher number of CA repeats (Mohamed et al. 2005a). Concerning 
the association with skin rash, unfortunately, the target capture method used by myself could 
not reliably capture repeat sequences and thus the analysis of the CA repeat length was not 
achievable. Therefore, in our study this region was even excluded from our target region. But 
shorter repeat length was reported in a few studies to be associated with occurrence of skin rash 
and was nominated as a biomarker for prediction of the skin rash and the outcome (Huang et al. 
2009). However, further studies including the first report of our study (Parmar et al. 2013) and a 
prospective study (Loupakis et al. 2014) could not reproduce these results. 
In addition, the structure of chromatin in intron 1 has convinced the scientists to analyze the role 
of intron 1 in EGFR gene transcription (Chrysogelos 1993). Intron 1 has DNase I hypersensitive 
sites, which are believed to be associated with important regulatory elements. These DNA 
sequences are exposed and accessible in chromatin structure, which makes them possible 
regulatory elements. Many transcription factors are found to interact with these regions 
(Chrysogelos 1993).  
Furthermore, EGFR SNP rs73420732 along with rs28557040 (another highly skin rash associated 
SNP) occurs at the region predicted to be important for transcription initiation and elongation. 
These predictions are based on the histone modifications found in chromatin structure of normal 
human keratinocytes. A study published in 2011 analyzed the chromatin structure of 9 human 
cell lines and consequently predicted their probable functions (Ernst et al. 2011). Among these 
cell lines there was a normal human keratinocyte line which we assume to be the primary suspect 
in formation of EGFR inhibition mediated skin rash. Histone modifications are changes in histone 
proteins which are specific to cell types and are believed to determine the function of different 
segments of genome. These modifications include: methylation, acetylation, and 
phosphorylation (Bannister and Kouzarides 2011). Methylation is a modification on histone 
proteins which tends to have regulatory properties. In the methylation process, methyl-groups 
are added to lysine or arginine residues of these proteins. Methylation of histone proteins makes 
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them targets for proteins with specific domains for identification of these sites. As an example 
trimethylation of lysine 4, which is a character of promoter regions which are found by 
transcription factors (Roidl and Hacker 2014). The region in which rs73420732 and rs28557040 
exist, is predicted to be the beginning of EGFR transcription elongation (transcription transition 
site) (Figure 4.1.2). Second and third most significant SNPs in this phase, rs57620875 and 
rs7784637, were predicted to be located in a region with strong enhancer activity. Although the 
data is newly introduced and needs to be more extensively surveyed, the regulatory role of these 
regions and the impact of genetic variations on this role could not be ruled out. As these 
variations occurred mostly in the no skin rash group, we hypothesized that changes in these 
regulatory regions result in the impairment of EGFR expression and therefore lower sensitivity of 
these cells to the EGFR inhibition.  
 
Figure 4.1.2. Predicted function of regions of EGFR SNPs with lowest P value in normal human keratinocytes. Black lines present 
the position of EGFR SNPs which were found to have significant association with presence of skin rash; orange, yellow and green 
bars show strong enhancer regions, weak enhancer regions and transcription transition regions, respectively (Ernst et al. 2011). 
These predictions are based on histone modifications found in these regions’ histones in normal human keratinocytes. As an 
example 4_strong_enhancer refers to sites with histone 3 lysine 4 mono- and di-methylation along with histone 3 lysine 27 
acetylation. Transcription transitional region is the position from where attachment of polymerase complex starts the elongation 
process. These functions have been suggested by considering chromatin modifications found at these positions in human 
keratinocyte cell. For further description in this regard please refer to (Ernst et al. 2011).  
  
Intron 1 of EGFR gene 
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Two common variations upstream of transcription start site were suspected to be predictors of 
skin rash after therapy. These two are EGFR -191 C/A and EGFR -216 G/T polymorphisms. 
However the promoter region was included in our target region, we had no coverage at this 
region for unknown reasons (Figure 4.1.3). 
 
Among SNPs in genes other than EGFR which were highly associated with skin rash, there is 
PIK3R1 rs3730089 which caused a M326I amino acid substitution in regulatory subunit 1 of 
phosphatidylinositol 3-kinase (PIK3R1). Following EGFR activation, PIK3 is activated via an 
adaptor protein (IRS-1). PIK3 regulatory subunits bind to this protein which results in activation 
of the downstream signaling. M326I amino acid substitution was more prevalent among the 
group with skin rash (26% vs 10%) in this study. Functional studies found decreased expression 
of PIK3R1 and yet on the other hand increased attachment to IRS-1 which activates the PIK3 
downstream signaling following this variation (Almind et al. 2002, Luo and Cantley 2005). M326I 
was also found to be associated with colon cancer (Li et al. 2008); however studies performed 
afterwards could not find a significant association of this SNP with prostate cancer (Paradis et al. 
2003) or endometrial cancer (Wang et al. 2012). The mechanism in which this variation may cause 
higher sensitivity to EGFR therapy, are remained to be understood. Higher activity of PIK3 
downstream signaling which possibly occurs in the skin cells with this variation, may make them 







Figure 4.1.3 Lack of coverage of EGFR promoter region. Although the promoter region was targeted, no reads were found. 
Presented sample has one of the highest number of reads 
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4.2 Second analysis phase: Genomic variants predisposing to high-grade skin rash 
In the second phase of analysis, patients were grouped into high grade skin rash (grades 2-3) and 
low grade rash (grades 0-1) to survey the association of variations with severity of rash. In this 
phase, 34 SNPs have reached significance level of 0.05. The most significant SNP was MAPK1 
(ERK2) rs13515. This SNP which was not in LD with other SNPs which were found in this gene. 
Other four MAPK1 SNPs were associated with severe skin rash and were linked considering r2>40.  
Rs13515 is the substitution from C to T in 3’ UTR of ERK2 gene. No report has been found about 
the function of this variation. In our study 54% of patients with no or low grade skin rash were 
carriers of this variation and on the other hand 21% of patients with high level skin rash were 
carriers of this variation. The 3’ UTR region is characterized with its role in gene expression by 
altering the mRNA’s processing, stability, and translation efficiency (Zhao et al. 2011). It contains 
several sequences that are involved in gene expression, including microRNA response elements 
which are responsible for binding of miRNAs and affect the post transcriptional gene expression. 
The 3’ UTR region of MAPK1 or ERK2 has been found to be targeted by a number or miRNAs. The 
MEK-ERK pathway has been shown to be regulated by miRNAs (Perry et al. 2009, Zheng et al. 
2012). In addition miRNA miR-199a has been shown to target MAPK1 mRNA and lower the 
expression of ERK protein (Kim, S et al. 2008). However no miRNA has been reported to target 
the position of rs13515 in MAPK1 RNA transcript (3975th position in the 5594 base transcript) to 
the best of our knowledge. The mechanism in which a possible binding miRNA could lower the 
sensitivity of skin cells to EGFR inhibition is yet to be understood. 
 
4.3 Common SNPs in both phases of analysis 
Eight SNPs: rs6970262, rs1404908, rs4947965, rs33933140, rs7796872, rs1137188, rs13515, and 
rs6593202 were associated with skin rash in both analysis phases. All of these SNPs were 
relatively frequent (MAF>20%). Among these SNPs, AKT2 rs33933140 (the only functional 
variation) which causes I136T amino acid substitution was more common among the patients 
with skin rash. As mentioned earlier, Tan et al. have suggested that baseline level of pAkt is 
probably a predictor of appearance of rash in patients receiving EGFR inhibition. They compared 
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the baseline pAkt level in 18 breast cancer patients prior to receiving erlotinib. Baseline pAkt was 
significantly higher in patients with no rash compared to patients with grade 1-2 rash (Tan et al. 
2008). However regarding rs33933140, a search in the literature did not result in a study which 
has investigated the effect of this variation. Though this SNP is localized in the linker region 
between pleckstrin homology (PH) domain and the kinase domain of Akt2 protein, it has been 
predicted to be damaging for protein function by the prediction tools. Higher skin rash prevalence 
among the patients with this variation is probably the result of decreased Akt phosphorylation 
(lower pAkt) subsequent to this amino acid substitution. It is also important to mention that this 
variation caused amino acid exchange in the protein coded by one of the 42 AKT2 transcripts. 
 
4.4 Previously reported skin rash biomarker rs2227983 
An amino acid substitution variation rs2227983 in EGFR was previously reported to be associated 
with skin rash (Parmar et al. 2013). This variation substitutes arginine to lysine at 521th amino 
acid of 1210 amino acid EGFR protein. In this study this variation was not found to be associated 
with skin rash. This result is compatible with results from several studies. McKibbin et al. surveyed 
this polymorphism in pooled data from five pediatric clinical trials of gefitinib. They dichotomized 
their patients similar to the phase two of our analysis (McKibbin et al. 2010). They could not find 
an association between this SNP and skin rash. As well, a phase 3 trial of erlotinib in pancreatic 
cancer patients could not find an association between this SNP and skin toxicity (Boeck et al. 
2013). They had a dichotomization similar to our first phase of study. Rudin et al (Rudin et al. 
2008) and Huang et al. (Huang et al. 2009) have reached similar results in NSCLC patients .  
 
4.5 Novel functionally damaging variations 
We found a previously not reported variation in EGFR (as our major cancer predisposing gene) 
which substitutes proline to threonine at amino acid 560. The codon change is CAC [C/A]CA GAG 
at position 55231472 in chromosome 7. This substitution, which resides in a furin-like cysteine 
rich domain, is involved in the process of signal transduction by receptor tyrosine kinases. This 
region is believed to play a role in EGFR dimerization which happens immediately after EGFR 
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activation (Raz et al. 1991). We suggest that this variation can be a causal rare mutation, which 
can eventually contribute to cancer formation. Other novel variations which cause amino acid 
substitution and are predicted to be damaging, are MTOR R2152H and MAPK1 D336S. These 
variations are located in protein kinase domains of the corresponding proteins and result in loss 
of function. It is also important to state that the predictions are not 100% true and many found 
to be damaging variations are fully functional and vice versa. 
 
4.6 Runs of homozygosity 
We observed a patient who had no heterozygous genotypes in EGFR region. Subsequently, we 
surveyed the depth of coverage at this position which might have been a reason for not calling 
heterozygote genotypes. However, the coverage at this subject’s resequencing was not optimal 
(20x coverage for 52% of target region); it was sufficient for calling 721 genotypes at this position 
(including 82 homozygote variant genotypes).  
Regions of runs of homozygosity are possibly caused by autozygosity or copy number variation. 
Autozygosity is defined as inheriting two chromosomal segments that are identical (one from 
each parent) from a common ancestor. On the other hand, small chromosomal deletions may 
also cause a similar genotype. Chromosomal deletions can result in regions with loss of 
heterozygosity due to losing one copy of a gene locus. When performing SNP arrays with 
microarray, copy number variation can be simply distinguished from autozygosity. When doing 
deep sequencing, however – if the application is not designed for identification of copy number 
variation – distinguishing between these two processes is not always possible. In the present 
study, gene copy number variation taqman assays can be used to distinguish between the stated 
processes. 
In both cases of autozygosity or copy number variation this patient is susceptible for cancer 
formation. We surveyed the available phenotypes of this patient to identify any extreme 
phenotypes. This patient had a low survival after treatment start date (111 days) compared to 
mean survival rate. However, regarding skin rash (grade 1 occurred in this patient) or diarrhea 
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(grade 0) no remarkable phenotype was observed. No variations occurred in exon regions of this 
patient within the germline genome.  
4.7 Statistical issues regarding analysis of association of EGFR inhibition related skin 
toxicity and genetic variations 
Study design and statistical analysis to find the genetic basis of skin rash variability seems to be 
challenging as the rash is developed in about 60-80% of patients receiving EGFRIs. In this situation 
an association study has to be performed in a sample population with three to four times case 
size compared to control size. In the present study, 19.8% of patients were affected with rash. A 
significant association would only be achievable in case of a strong underlying association of a 
common variation and not multiple rare variations. In addition, correction for multiple testing 
causes a further power loss in analysis. Another measure which has been taken for overcoming 
this problem is dichotomizing patients in two groups of rash grade ≤1 and >1, which will result in 
a relatively similar case-control sample size. However, this dichotomization may or may not 
reflect the reality considering the causality of variations in formation of rash; as the underling 
mechanisms are not well-known.  
 
4.8 Gene-based and pathway-based analysis 
An additional analysis which best suites the study of rare variations is gene-based analysis. Rare 
variations have a small but effective impact on a disease or phenotype. Each of these variations 
may not reach a significant level when studying their association with a phenotype, specially 
when the sample size is small. The common disease/rare variations hypothesis considers the 
additive effect of these variations in contributing to a disease or phenotype. To perform this 
analysis only predicted to be damaging rare SNPs should be enrolled in the analysis (Do et al. 
2012). After Bonferrori’s correction for multiple testing considering the 30 genes, P value of 
0.0017 was found as the level of significance. Kirino et al. also used correction by the number of 
targeted genes in their study (targeted deep sequencing of loci found by GWAS to be associated 
with Behcet’s disease) (Kirino et al. 2013). Performing this analysis for our study – considering 
damaging rare variants predicted by any of SIFT, Provean or Polyphene2 – we could not find an 
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association between skin rash phenotype and genes with loss-of-function variants. In gene-based 
tests the I value is reported which represents the lowest P value in this analysis. However this 
value did not reach the corrected level of significance, which highlights the small sample size as 
a reason for the low power of finding statistical significance. To overcome this problem studies 
with higher sample size are recommended. 
In pathway-based analysis an association was found between high grade skin rash, and PI3K/Akt 
pathway variations. This finding in addition to the other PIK3R1 SNP rs3730089, which was found 
to be associated with presence of skin rash, introduces PIK3R1 as an important skin rash 
determinant. Additionally, presence of skin rash in patients receiving PI3K inhibitors is another 
proof for involvement of PI3K in skin rash pathology (Mayer et al. 2014). In Mayer et al.’s study 
40% of patients receiving the buparlasib (a PI3K inhibitor) developed skin rash. The fact that only 
a fraction of patients developed rash, highlights the possible role of PI3K genetic variations in 
these patients.  
 
4.9 The unsolved mystery of association between skin rash and survival  
Survival of patients receiving EGFR inhibitors is associated with the skin rash. Figure 4.9.1 displays 
this association in the present study. The reasons behind this association are not well understood. 
Shorter intron 1 CA repeat polymorphism was reported to increase the expression of EGFR in 
vitro (Mohamed et al. 2005b). To explain the association of CA repeat with skin rash and also 
survival, scientists have hypothesized that the higher expression of EGFR causes the susceptibility 
of both keratinocytes and cancer cells to EGFR inhibition (Mohamed et al. 2005a). However 
several studies could not reproduce the association of CA repeat and skin rash or survival (Parmar 
et al. 2013). In addition – knowing that inflammatory response is an important part of skin rash 
pathology – a more extensive inflammatory response against tumor cells has also been suggested 
to be a reason for a better survival in patients with skin rash (Albanell et al. 2002). 
The role of confounding factors in the correlation found between these agents’ skin toxicity and 
survival cannot be overlooked. Firstly the rash is known to be a dose-dependent side effect. 
Difference in the bioavailability of the drugs in between the patients may cause this correlation. 
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To clarify, higher plasma levels of the drug in the patients – caused by individual difference in the 
drug metabolizing enzymes – may cause better efficacy and development of skin rash. There are 
recent studies which use a dose-to-rash approach, meaning that they escalate the dose of EGFRIs 
until the patients develop skin rash (Ho et al. 2011, Renouf et al. 2014). However the dose 
escalation was well tolerated; these studies did not find a benefit in efficacy for this approach. As 
another confounding, relatively low survival of some patients may not provide enough time for 
the development of rash. Therefore the association between no rash and low survival may be 
falsely identified. Nevertheless, the trend towards better survival with higher grades of skin rash 
cannot be attributed to the mentioned probable confounding. 
As the majority of variations were rare in the present study, testing the association of these 
variations and survival was not possible. Though a descriptive analysis was performed on 
nonsynonymous variations (the functionally most important variations) regarding their effects 
on patients’ survival, and average of patient’s maximum skin rash and diarrhea in the observation 
period. These variations were mostly rare; however, there were a few common variations. 
Regarding the common variations, carriers of alternative allele of rs3730089 in PIK3R1 gene 
(M326I) had a better survival (homozygous variant genotype 314 days, heterozygous genotype 
260 days) compared to non-carriers (231 days). Interestingly, 24 out of 26 carriers developed skin 






Figure 4.9.1 Survival plot of the patients in our study (in days) categorized the maximum skin rash grade occurred during the 
follow-up. Patients with higher rash grades had a better overall survival rate. 
 
4.10 Outlook 
The strongest associations were found between a number of EGFR intron 1 SNPs and skin rash in 
this study. Several approaches can be used to survey the effects of these SNPs. To investigate 
whether these positions are transcription factor binding sites, electrophoretic mobility shift assay 
(EMSA) can be utilized. In this method, protein binding of the intronic DNA sequence can be 
tested for both reference and variant sequences. In addition, as intron 1 was found to have an 
important role in gene expression, effects of these intronic variants can be determined by 
reporter gene assays. 
An Akt2 nonsynonymous SNP (rs33933140, I136T) was associated with both presence and high 
grade skin rash. This variation has been predicted to be damaging for protein function by the 
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prediction tools. Effects of this variation (such as chemokine expression or apoptosis) can be 
investigated using siRNAs for silencing Akt2 protein expression in normal human keratinocyte cell 
culture. Additionally, the kinase activity of wildtype and variant Akt2 can be investigated. In order 
to survey this activity, the wildtype and the variant protein can be expressed in a cell line which 
has low or no baseline expression of the selected kinase. Subsequently, using antibodies for 
phosphorylated Akt2 substrates this activity can be investigated. Human Akt2 knockout haploid 
cell line is also available for further investigation (Burckstummer et al. 2013). 
To investigate the effects of variations in PIK3R1 (or more generally PI3K), the variant proteins 
can be expressed in yeast and then affinity of PIK3R1 to IRS-1 (adaptor protein between EGFR 
and PI3K) or to the kinase subunit PIK3CA or PIK3CB (the catalytic subunits of PI3K) can be 
analyzed. Moreover, to analyze the effects of these variations on downstream signaling, the pAkt 
level and also kinase activity of Akt protein can be examined (Almind et al. 2002).  
To the best of our knowledge, a model for skin rash has not been produced. Potentially immune 
cell infiltration via chemoattraction can be investigated using keratinocyte cell cultures and 
chemotaxis assays. The most well-known chemotaxis assay is the two-chamber assay. In this 
assay keratinocytes and immune cells are placed in two different chambers for culture, but they 
share the culture medium (Boyden 1962). Between two chambers, there is a filter only allowing 
a certain size of motile cells to migrate to the keratinocyte chamber. Along with chemokine 
expression after EGFR inhibition, chemoattraction can be investigated. Using this model a wide 
screening for relevant chemokines can be performed. 
 
4.11 Study limitations 
A major pitfall while performing Ion torrent sequencing is the presence of homopolymer issue 
which also existed in pyrosequencing (Michils et al. 2012). Using Ion torrent sequencing 
nucleotides are added one after another and the alteration of PH is recorded. PH alterations are 
indicators of a reaction in which the added nucleotide firstly has matched the template and 
secondly is added to the under-construction strand. In case of a nucleotide repeat, multiple 
reactions happen after addition of one nucleotide since the following template nucleotide in the 
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template is also complimentary to the added nucleotide. This phenomenon results in higher PH 
change compared to the PH change when only one reaction has occurred (in case of no-repeat). 
Distinction of number of nucleotides is not confidently made in a repeat sequence using this 
method. Therefore, the presence of homopolymer regions produce artifacts which resemble 
insertions and/or deletions (Tarabeux et al. 2014). To resolve this problem, studies have taken 
several measures such as accepting higher sequencing qualities or filtering them out from the 
study (Abou Tayoun et al. 2013, Ross et al. 2013, Tarabeux et al. 2014). Accordingly, we filtered 
out the homopolymer regions and all of the insertion/deletions from the study which results in 
lower false positive results but less coverage of target region.  
 
4.12 Conclusion 
In conclusion, we have found 1437 single nucleotide variations in 380kb targeted region of 126 
patients who underwent EGFR inhibitor therapy. Three SNPs in a regulatory region of intron 1 of 
EGFR were found to be strongly associated with the presence of rash. Furthermore, an ERK2 
(MAPK1) 3’ UTR variation was found to be associated with high levels of skin rash. Pathway-based 
analysis of rare variations suggested the PI3K pathway to be involved in the rash etiology. In 
addition to this finding, rs3730089 in PIK3R1 was found to have an association with skin rash and 
also a trend towards a better survival was found in patients having this variation. 
A number of deleterious variations in EGFR pathway were announced for the first time including 
EGFR P560T, MTOR R2152H, and MAPK1 D336S which can be causal rare variations for cancer 
formation. Previously reported candidate biomarker variations for EGFR inhibition related skin 
toxicity, rs2227983 which causes a single amino acid substitution was not significantly associated 
with skin toxicity and other biomarkers such as intron 1 CA repeat, -216G/T, and -191C/A could 





The development of targeted therapy has promised a new era in cancer therapy by improving 
response rates and fewer side effects of the therapeutics on normal cells. As the involvement of 
EGFR was noticed in several epithelial tumors, this receptor was identified as a target for cancer 
therapy already in 1983. However, EGFR inhibition seems to have its own class of side effects 
such as skin toxicity and diarrhea. These side effects remarkably occur only in a subgroup of 
patients with remarkable severity. Interestingly, the occurrence of skin toxicity was in almost all 
studies correlated with drug response and survival rate in treated patients. In this study we aimed 
to analyze the genetic variations in EGFR signaling pathway in patients receiving EGFR inhibition 
therapy using a deep sequencing method. If variants could be identified which significantly 
predicted skin toxicity, analysis for such variants would be used as biomarkers for individual drug 
dosing. In addition, the relationship between variants and phenotypes might contribute to our 
understanding of the skin rash with EGFR inhibition therapy. 
Thirty genes reflecting the EGFR downstream pathway (PI3K/Akt and Ras/MAPK) and other genes 
involved such as IL8 and its receptors were targeted for resequencing. The whole EGFR gene 
along with 2000 bp of its promoter region was one of the targets. The total size of the re-
sequenced EGFR gene was 196300 base pairs. For the remaining 29 other genes involved or 
presumed to be involved in rash physiopathology, the exons along with about 500 bp of the 
respective promoter regions were selected. We studied DNA samples from 126 patients who had 
been treated with EGFR inhibitors and in whom the adverse effects were characterized in detail. 
Before deep sequencing analysis was performed, three major steps: library preparation, target 
enrichment and template preparation were performed. Deep sequencing was executed using Ion 
Torrent Personal Genomics Machine TM (PGM). Variant calling was done by Torrent Variant Caller 
software. Statistical analysis was performed to survey the association of the identified variants 
with skin toxicity, diarrhea and overall survival. 
Total 1437 single nucleotide variations were identified. These variations were present in more 
than 50% of subjects. From all variants found, 45% had less than 1% minor allele frequency and 
65% of the variations had less than 5% minor allele frequency. Average minor allele frequency 
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was 8.79% in this study. Three hundred and seventeen SNPs (22%) were not listed in the dbSNP 
138. Three SNPs in intron 1 of EGFR were found to be strongly associated with the presence of 
rash. Intron 1 of EGFR was already shown earlier to be an important regulatory region for EGFR 
transcription. Furthermore, an ERK2 variation was found to be associated with high levels of skin 
rash. Pathway-based analysis of rare variations suggested the PI3K pathway to be involved in rash 
etiology. In addition to this finding, rs3730089 in PIK3R1 was found to have an association with 
skin rash and also a trend towards the better survival was found in patients having this variation. 
These two findings suggest the involvement of PIK3R1 in EGFR inhibitor induced skin toxicity. 
A number of deleterious variations in EGFR pathway were announced for the first time including 
EGFR P560T, MTOR R2152H, and MAPK1 D336S which can be causal rare variations in cancer 
pathology. Previously reported biomarker candidate variations for EGFR inhibition related skin 
toxicity such as intron 1 CA repeat, -216G/T, and -190C/A were not studied and the rs2227983 
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